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Background: Oxytocin is a life-saving, high-alert medication.1 While frequently used in obstetric 
practice to induce or augment labor as well as prevent or treat postpartum hemorrhage, little is 
known about the levels and patterns of oxytocin use in obstetric practice in the United States. 
The purpose of this dissertation is to describe how oxytocin is being used in intrapartum care in 
the US and what are the patters of association with postpartum hemorrhage and primary cesarean 
section. 
Methods: This study is a secondary data analysis of the Consortium on Safe Labor Database 
from the National Institute of Health. The analytic sample consisted of data from women 
admitted for delivery at 9 of 12 study sites that collected any oxytocin data; women were 
excluded from analysis if admitted for a pre-labor cesarean section. Descriptive statistics were 
used to describe oxytocin exposure patterns. Associations between oxytocin exposure and 
postpartum hemorrhage and primary cesarean section were assessed using multivariable logistic 
regression. The regression models were then used to predict probabilities. 
Results: 162,201 births were included in the analysis. Of these, oxytocin dose information 
had been collected for 54,456 births. 65.7% of women in the sample were exposed to oxytocin 
during their labor. 2.9% and 14% of women had a PPH diagnosis and primary cesarean, 
respectively. 66% of births in the sample involved oxytocin exposure during labor. The 
probability of postpartum hemorrhage was significantly increased at 6,000 mU of total oxytocin 
dose exposure, while the probability of primary cesarean section was significantly increased at 
4,400 mU of total oxytocin dose exposure. Maximum oxytocin infusion rates greater than 10 
mU/min and 20 mU/min were associated with increased risks of primary cesarean and 
postpartum hemorrhage, respectively. 
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Conclusion: The results suggest that oxytocin may be used frequently and has a dose-dependent 
association with two important obstetric outcomes: postpartum hemorrhage and primary cesarean 
section. Prospective studies are needed to corroborate this study’s findings and to examine 
whether oxytocin is being used inappropriately as a way to develop clinical guidance and 
interventions on its adequate use in obstetric practice. 
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INTRODUCTION AND BACKGROUND 
Introduction 
Oxytocin is the hormone associated with orgasm, labor contractions, milk let-down and social 
bonding.2  Oxytocin in its synthetic form is commonly used in obstetric practice to induce or 
augment labor, as well as prevent or treat postpartum hemorrhage (PPH). 
PPH is a leading cause of maternal morbidity and mortality.3  While maternal mortality 
rates have decreased globally, rates of atonic PPH, the most common type of PPH, have 
increased in a number of high-resource countries (e.g., Australia, Canada, Ireland, US, UK).4–11  
Morbidity related to PPH is significant and may include outcomes ranging from anemia and 
difficulty breastfeeding to loss of fertility, postpartum depression and post-traumatic stress 
disorder.12,13  Observational studies in the United States have found that patient risk factors for 
PPH explain little of the rise in atonic PPH.4,5,8,10,11  Most of these studies have used the National 
Inpatient Sample, which provides demographic data and International Classification of Disease 
(ICD) codes; the ICD, however, does not contain all codes pertinent to PPH and associated 
risks.5,8,10,11  Specifically, the ICD does not contain codes for labor augmentation and, especially, 
for either induction or augmentation performed with synthetic oxytocin.  Exposure to synthetic 
oxytocin in labor is an established risk factor for atonic PPH14–16 and the extent of synthetic 
oxytocin use in obstetric practice may be increasing.17,18  Oxytocin use is also associated with 
another significant maternal outcome and focus of national quality initiatives, the primary 
cesarean section.19–22 
Currently, 32% of births in the United States are cesarean sections.23  Cesarean sections 
are major abdominal surgeries associated with a number of adverse outcomes, including an 
increased risk for hemorrhage, infection, neonatal respiratory distress and complications with 
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future pregnancies.24,25  Reducing primary cesareans in low-risk women is a quality indicator for 
the Center for Medicare and Medicaid Services’ Obstetric Core Measures, as well as a Healthy 
People 2020 goal and an initiative for the American College of Nurse-Midwives and the 
American Congress of Obstetricians and Gynecologists25–28.  Oxytocin use is an independent risk 
factor for cesarean sections.19–22,29 
Background 
Induction or augmentation of labor is an independent risk factor for PPH.8,30–32  Oxytocin is the 
drug commonly used for both induction and augmentation, and its use in labor may explain much 
of the increase in atonic PPH in high-resource countries.15  Similarly, labor induction is an 
independent risk factor for primary cesareans, with oxytocin being the medication commonly 
used for induction.19–22  Induction and augmentation rates in obstetric practice in the United 
States are high, but both terms cover a wide array of procedures (e.g., mechanical induction with 
cervical dilators to augmentation with artificial rupture of membranes to the use of oxytocin).33–
35  The incidence and pattern of oxytocin exposure in laboring women in hospitals in the United 
States is unknown.  Oxytocin is a high-risk medication1 and it is possible that its use is the main 
reason why induction and augmentation are independent risk factors for PPH and primary 
cesareans.  In order to address the high rates of PPH and primary cesareans, improve the quality 
of obstetric care, maternal and neonatal outcomes, oxytocin use must be better understood. 
Purpose of Dissertation Research 
The purpose of this study is to examine the use of synthetic oxytocin in obstetric practice and its 
patterns of association with postpartum hemorrhage and primary cesarean section by using a 





Aim 1a:  To examine the incidence of synthetic oxytocin exposure in women admitted for labor 
in a large nationwide sample of hospitals.  
Aim 1b:  Among women who received synthetic oxytocin, to describe synthetic oxytocin 
exposure via “total dose”, stratified by indication and patient characteristics.   
Hypothesis:  The majority (i.e., > 50%) of hospital labors observed will include synthetic 
oxytocin exposure.  The primary use of synthetic oxytocin will be for labor augmentation. 
Aim 2 
Aim 2a:  To examine the relationship between synthetic oxytocin exposure and postpartum 
hemorrhage accounting for patient-, provider- and hospital-level variables. 
Aim 2b:  For those that received synthetic oxytocin, examine the relationship between amount 
received as measured by “total dose” and postpartum hemorrhage accounting for patient-, 
provider- and hospital-level variables. 
Aim 2b Sub-Aim:  Explore whether there is a clinically-relevant point of oxytocin exposure 
associated with the risk of PPH.  
Hypothesis: Increased dose of synthetic oxytocin will be associated with higher risk of PPH 
among women treated independent of patient characteristics. 
Aim 3 
Aim 3a:  To examine the relationship between the receipt of synthetic oxytocin and unscheduled 
cesarean accounting for patient-, provider- and hospital level variables. 
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Aim 3b:  For those that received synthetic oxytocin, examine the relationship between amount 
received as measured by “total dose” and unscheduled cesarean accounting for patient-, provider 
and hospital-level variables. 
Aim 3b Sub-Aim:  Explore whether there is a clinically-relevant point of oxytocin exposure 
associated with the risk of a primary, unscheduled cesarean section. 
Hypothesis:  Oxytocin exposure will be positively associated with the occurrence of primary, 
unscheduled cesarean sections independent of patient-level variables. 
Significance of Research 
The significance of the proposed research lies in its focus and method.  Oxytocin may be 
the most commonly used drug (apart from pain medications) in U.S. obstetric practice, but little 
research has been done on exactly how and to what extent oxytocin is used.  Since oxytocin 
exposure is an independent risk factor for both PPH and primary cesareans, understanding how it 
is used is critical for developing interventions to address significant causes of maternal morbidity 
and to improve quality care and outcome measures.  Oxytocin exposure is difficult to measure 
and the proposed research will use total dose, a newer measure36,37 and one that holds promise 
for understanding clinically relevant points of oxytocin exposure.  The use of total dose in this 
research will not only allow a more nuanced understanding of oxytocin’s effect on important 
outcomes but will also contribute to the science regarding the use of this method for future 
research. This study also uses regression models to predict probabilities, allowing for easier 
interpretation that more accurately depicts risk, especially when the outcome of interest, such as 




 Joanne Duffy’s Quality-Caring Model38 (QCM) provides the conceptual framework for 
this research.  The QCM combines “theories of health care quality and relational aspects of 
nursing”38(p30) within Donabedian’s39 structure-process-outcome framework.  Duffy38 argues that 
a focus on quality health care in conjunction with caring (the relational component of healing) is 
necessary to improve the process and outcomes of health care in the United States.  In this 
model, patient, provider and system level factors interact and affect the process and outcomes of 
health care.  Patient, provider and system factors significantly affect the process and outcomes of 
obstetric care in the United States.  The use of this model provides a framework for 
understanding which variables and outcomes to include in the research.  Not all of the variables 
indicated in the framework will be included in this particular study; the framework is then a 
guide for next steps in the research (e.g., examining provider and system-level factors in the 
structure and outcome).  Health disparities are rampant in U.S. obstetric care and the QCM 
provides an excellent framework for understanding how provider, patient and system factors 
might interact in the creation and perpetuation of health disparities.  The QCM model was 
adapted with the author’s permission.40 “System relationships” was added to Process, based on 

























































Oxytocin Prevalence in US Obstetric Management and Its Association with Postpartum 
Hemorrhage and Primary Cesarean Section: A Scoping Literature Review 
Introduction 
Oxytocin is the hormone associated with labor contractions, milk let-down, orgasm and social 
bonding.2  In synthetic form, oxytocin is one of the most powerful drugs in the obstetric 
pharmacopeia and one of only a few high-alert medications.1,41 While oxytocin is the first choice 
for prevention and treatment of postpartum hemorrhage globally, it is also used to induce and 
augment labors, especially in high-resource settings. The benefits of oxytocin use in labor 
include shorter duration of labor42,43 and the possibility of decreasing the rate of cesarean 
sections43–48. The adverse effects of oxytocin use in labor include postpartum 
hemorrhage,31,36,49,50 uterine rupture51, neonatal morbidity47,52, cesarean section in low-risk 
women (secondary to fetal distress)53–58, episiotomies59 (and severe lacerations60,61) and 
breastfeeding difficulties62–66. There is also a growing body of literature examining the 
epigenetic effect of fetal oxytocin exposure67,68, as well as the association of exposure with 
childhood development69,70 and disease71. Many of these effects, or the extent of these effects, 
are still being debated due in part to the inconsistency of definitions and measurements, as well 
as the varying quality of the available research. This review will examine how oxytocin is being 
used to induce or augment labor, especially in high-resource settings, its measurement in 
research, and its association with a leading cause of maternal morbidity and mortality, 
postpartum hemorrhage, and a primary focus of quality improvement efforts, the reduction of 




A literature search was conducted in PubMed, CINAHL, Web of Science and Embase (see Fig. 
1). The search was limited to human-only studies conducted in the past 5 years and published in 
English. Additional articles were found by reviewing references, including pertinent research 
published in the last 10 years and one article written in English and French. The search terms 
used were “oxytocin labor” (MeSH terms were used in PubMed); this yielded 2840 results, of 
which 2,640 were screened. Of the titles screened, 256 were selected for abstract review; 
ultimately 41 articles were included in the literature review. The review was conducted as 
pharmacoepidemiology scoping review. Articles were included for review if they examined or 
discussed the prevalence of oxytocin use in the intrapartum in high-resource settings or if they 
examined the effects of oxytocin use on the population. Articles were excluded if they focused 
exclusively on oxytocin use in the third stage of labor or if they did not discuss oxytocin 
specifically. Therefore, if a study examined induction or augmentation, but not oxytocin 
specifically, it was excluded from the review. This decision was made because both induction 
and augmentation are heterogenous categories including an array of medications and procedures 
and, therefore, do not specifically reflect the prevalence or effects of oxytocin use. Literature and 
Cochrane reviews were eligible for inclusion. Mapping was used to extract the main themes in 
the oxytocin use literature to organize the presentation of results. The main themes included: use 
prevalence, exposure measurement, maternal and fetal/neonatal effects and safety. Several 
maternal and fetal/neonatal effects of oxytocin were identified in the literature. Postpartum 
hemorrhage and primary cesarean section outcomes were chosen because they are prevalent and 
intimately linked to the physiology of oxytocin and the rationale for its intrapartum use. “Safety” 
as a theme included research examining interventions to mitigate the amounts of oxytocin used 
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and its effects, litigation, staffing and inappropriate use of oxytocin. The use of oxytocin in labor 
without a medical indication was frequently mentioned in studies looking at oxytocin prevalence; 
other safety topics were not included in this review as they focused predominantly on changing 
the use of oxytocin to effect outcomes. 
Results 
41 studies were included in the final literature review. The studies were conducted in Europe, the 
United States, Australia, Canada, Turkey and South America (one study of hospitals in Uruguay 
and Argentina). 32 of the 41 studies were published in the last five years and most of the study 
data was collected in the 2000s-2010s. The majority of the studies were retrospective cohort 
studies, followed by some case-control and prospective cohort studies. Many of the studies were 
secondary data analyses of existing datasets. Three Cochrane and three literature reviews were 
also included in the current literature review. 
Prevalence 
In a review of the literature, secondary data analyses and a retrospective cohort study found 
variation in oxytocin use, but overall evidence indicates that around half of the women in labor 
in the United States will be exposed to exogenous oxytocin in labor and, therefore, most children 
born in the United States have been exposed to exogenous oxytocin in vitro.41,72,73 No 
prospective cohort studies were found which examined the use of oxytocin in intrapartum 
management in the United States as their primary purpose. Of the seven studies mentioning the 
prevalence oxytocin use, none specifically examined oxytocin, but rather cesarean delivery 
levels 33,72, the impact of early admission on interventions74, labor35,73 and induction75,76 patterns. 
These studies indicate that oxytocin is the most common drug used for induction and 
augmentation in the United States.35,73,75 With regards to induction of labor, one study using the 
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Consortium of Safe Labor database (N = 638,802) found that, at minimum, 65.8% of nulliparous 
and 62.8% of multiparous women undergoing induction were exposed to oxytocin.35(p486.e7) A 
much smaller study of 848 women, found that 73.7% were induced primarily with 
oxytocin.75(p407) Of the studies examining cesarean section, one reported oxytocin use varying 
from 66-68.3%72(p689.e3) among 7,845 women at ≥ 37 weeks gestation with singleton, vertex 
pregnancies and no history of cesarean section; the other study of 2,851 nulliparous women with 
vertex, singleton pregnancies attempting vaginal birth reported 57.3% of the study sample was 
augmented with oxytocin33(p7) Two studies examined contemporary labor patterns in the 
Consortium on Safe Labor database (2002-2008) and reported oxytocin augmentation ranging 
from 31%76 (of 98,359 women) to “nearly half” of 62,415 women73. Three of these studies used 
the Consortium of Safe Labor Database and reported very different numbers regarding oxytocin 
exposure based on their respective research question and primary outcomes and, therefore, 
sample composition.35,73,76 One other study (N = 216) found that half of the nulliparous women 
in spontaneous labor in the study were augmented with oxytocin.74(p31) 
In other high-resource countries, oxytocin use in the intrapartum is similarly common. 
Studies examining low-risk women in spontaneous labor found that overall oxytocin 
augmentation rates averaged between 40.5% - 58%.77–79 The lowest reported oxytocin 
augmentation rate was 26.4% of an Icelandic cohort.80 Low-risk nulliparous women in 
spontaneous labor had higher rates of oxytocin augmentation, ranging from a low of 32.4% in 
the Netherlands81 to 43.8% in Norway82 to 45.4% in Australia83 to 52.6% in Germany79 to 75% 
in Sweden78. Multiparous women who were low-risk were less likely to receive oxytocin 
augmentation in labor, but still had augmentation rates of 27%79 – 38.1%78.  
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Several studies indicate oxytocin is frequently used for augmentation without an 
appropriate indication, such as labor dystocia.78,79,84,85 Such use is considered inappropriate. A 
Swedish and a German study examining the management of prolonged labor84 and the sequence 
of labor interventions79 in low-risk women, respectively, found that oxytocin was not always 
used appropriately. Of 829 women in spontaneous labor in the Swedish study, 28% received 
oxytocin augmentation without evidence of prolonged labor84(p1). 40.5% of 3,055 low-risk 
women in the German study were augmented with oxytocin however not all of these met criteria 
for oxytocin augmentation.79(pp249, 253) Two further studies, in Norway85 and Sweden78, also 
concluded that oxytocin use for augmentation was not always appropriate. Of 747 low-risk 
nulliparous women in spontaneous labor in Norway, 42.5% of the 43.8% of women being 
augmented did not meet criteria for dystocia85(p364). Of 1,263 women in spontaneous labor in 
Sweden, 55% received oxytocin augmentation, with women being over- or under-treated for 
dystocia.78(p1353) Similar studies have not been conducted in the United States, to the best of our 
knowledge. 
Measurement 
Oxytocin exposure is frequently measured as a binary variable.6,35,90,91,46,74–76,86–89 Two studies 
conducted in 2011 introduced continuous measurement of oxytocin exposure via “total dose”50 
or “area under the curve”36. Total dose (milliunits, mU) is calculated by summing the products of 
each oxytocin infusion rate in milliunits/minute (mU/min) by the duration of that rate (min) for a 
given woman.36(p56.e2),50 As a continuous measurement, total dose is difficult to interpret, so both 
studies created a categorical variable based on total dose. Belghiti et al50. used the 50th, 75th and 
90th percentiles to create total dose categories; Grotegut et al.36 examined total dose in 5000 mU 
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increments. In addition to total dose, Belghiti et al.50 examined oxytocin as a binary variable and 
in terms of maximum infusion rate (mU/min) and total duration of exposure (min).  
In 2015, three studies used different methods to measure oxytocin exposure: total dose 
(mU)92, maximum infusion rate (mU/min)93 and a comparison of maximum infusion rate at 
greater or less than and equal to 20 mU/min94. Both studies93,94 that looked at rate did so in order 
to gather information to improve oxytocin protocols; none gave specific rationale behind the 
measurement method chosen. Two 2017 studies used a variety of methods for measuring 
oxytocin exposure: mean and maximum oxytocin infusion rate (mU/min), hourly and total 
oxytocin dose (IU and mU)95 and the duration of each specific infusion rate as well as total 
duration (min) of oxytocin exposure (min)96. In 2018, two studies97,98 used a variety of methods 
to measure oxytocin exposure. One study examined initial, average and maximum infusion rate, 
as well as duration, to examine the impact of instituting an oxytocin checklist on usage and 
outcomes.97 The other study used maximum oxytocin rate (mU/min), total duration (h), oxytocin 
product (mU/min*h [sic]) and total dose (mU) in order to determine whether the product of 
maximum rate times total duration would be a good surrogate for total dose.98(p79) All of the 
studies were retrospective cohort, case-controls or secondary data analyses. While there is no 
agreement in the literature, yet, regarding categories for oxytocin infusion rate and total dose, 
both measures promise a more detailed understanding of the effect of oxytocin on outcomes of 
interest in a manner that is easily interpretable for clinical practice. 
Effects 
Postpartum Hemorrhage 
Four studies36,50,99,100 specifically examined the relationship of intrapartum oxytocin 
exposure to postpartum hemorrhage. A secondary data analysis conducted in South America, 
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examined oxytocin exposure as a binary variable and found no association between intrapartum 
oxytocin exposure and hemorrhage risk, if women also received active management of the third 
stage of labor.100 A secondary analysis of 41,941 births in the United States measured oxytocin 
as a binary variable (i.e. maximum infusion rate was greater than 20 mU/min).99 The study found 
that receiving a maximum infusion rate greater than 20 mU/min was an independent predictor of 
uterine atony.99(pS86) These findings were corroborated by a case-control study of 3,240 women in 
France which found that the odds of a severe postpartum hemorrhage increased significantly at a 
maximum infusion rate of 10-15 mU/min (compared to no oxytocin) and then increased 
significantly again for a maximum infusion of > 15 mU/min.50(p4) This same study also examined 
oxytocin exposure as total dose  and found that the odds of severe hemorrhage, after adjusting 
for other variables, was three times greater for a total dose 2000-4000 mU and six times greater 
for a total dose above 4000 mU, compared to receiving no oxytocin.50(p4) Similarly, a case-
control study of 108 women in the United State, 54 with and 54 without severe postpartum 
hemorrhage, found that, after adjustment and compared to no oxytocin exposure, every 5000 mU 
increase in total dose was associated with a 58% increase in the odds of having a severe 
hemorrhage.36(p56.e5)  
A number of studies have examined oxytocin exposure and relationship with PPH as a 
secondary aim; all of these studies measured oxytocin exposure as a binary variable.31,85,88,89,101 
With one exception101, these retrospective studies, conducted in Switzerland89, Norway85, 
Turkey88 and France31, found that oxytocin exposure statistically significantly increased the odds 
of experiencing a postpartum hemorrhage while controlling for other risk factors.  
Two literature reviews102,103 and a mini-Cochrane review46 were retrieved during the 
search. The mini-Cochrane review, which was examining the effect of oxytocin augmentation in 
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women with epidurals on cesarean section rates and maternal morbidity, concluded that oxytocin 
exposure had “no effect on postpartum hemorrhage”.46(p760) The review, however, only included 
two studies with a grand total of 319 women; 226 of the women in one study were fully dilated 
(difficult to study oxytocin augmentation in this sample) and 93 of whom were dilated ≤ 6 cm 
(arguably, therefore, not in active labor according to recent research57,104).46(p760) The largest of 
these reviews, which examined 43 studies to understand the maternal effects of oxytocin 
augmentation, concluded that “…oxytocin administration during spontaneous labor is associated 
with a higher risk of postpartum hemorrhage, especially when the dose used during labor is high, 
the increment intervals are short, or the woman does not receive prophylactic oxytocin 
immediately around delivery.”103(p516) This review notes that the association between oxytocin 
exposure and postpartum hemorrhage has only been seen in observational studies, not 
randomized-controlled trials103(p515). It would be exceedingly difficult to design a trial that would 
randomize women to receive oxytocin that would also be ethical. A scoping review conducted to 
understand whether induction or augmentation prior to cesarean section increases the risk of 
postpartum hemorrhage reported not finding enough research to answer the study question.102 
The researchers did find two studies, however, which indicated that oxytocin exposure prior 
cesarean was associated with higher postpartum oxytocin doses necessary to control bleeding, 
which would suggest that oxytocin exposure is associated with a greater risk of bleeding 
postpartum.102  
Cesarean Section 
The magnitude of the association between oxytocin exposure and primary cesarean delivery 
varies in the literature. The most common study findings were that oxytocin increased the risk of 
cesarean section or did not reduce the incidence of cesarean section.48,58,83,85  Three studies found 
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that oxytocin exposure increased the risk of a cesarean section.58,82,83 Two studies examined the 
introduction of oxytocin protocols and found that the implementation of such a protocol led to 
decreased numbers of cesarean sections.44,56 One study found that oxytocin augmentation in 
nulliparous women with an epidural decreased the incidence of cesarean section; no mention was 
made of when oxytocin exposure started (i.e., before or after active labor).105 In all of these 
studies, oxytocin was measured as a binary variable. Oxytocin alone, and as a component of 
active management of labor, has been examined as a means to reducing the length of labor and 
the number of cesarean deliveries, but it’s dose-association with the incidence of primary 
cesarean sections in unknown.  
 Three separate Cochrane reviews found that, either: there was no statistically significant 
reduction in the use of cesareans caused by using oxytocin48; or, there was no increase in the 
number of normal deliveries106; or, that there was a small reduction in cesarean section, but that 
active management was “highly prescriptive and interventive”107(p2) for low-risk women. The 
Cochrane review of the active management of labor package which found a small decrease in 
cesareans included one-on-one nursing care.107 The effect of one-one-one care, which is known 
to reduce analgesic requirements and cesarean rates, was not delineated from the effects of 
oxytocin.107,108 The reviews were not able to take cervical dilation into consideration, and there is 
evidence that oxytocin exposure prior to active labor at 6 cm dilation may be a more significant 
risk factor for cesarean section, especially among nulliparous women, than oxytocin exposure at 
all.57 A more recent review, conducted for the development of clinical guidelines in France, 
concluded that active management of labor did not decrease the incidence of cesareans and that 




Oxytocin is a high-alert medication because of its potential to cause dose-association adverse 
outcoems.1,57(p32) Inappropriate use of oxytocin is noted in half of all paid obstetric litigation 
claims.57(p33),108 The World Health Organization reports augmentation is needed in less than 30% 
of labors110(pS270). In contrast, most women in the US and in other high-resource countries are 
exposed to oxytocin during labor. Studies from several European countries concluded that 
oxytocin is frequently used without an indication. A comprehensive understanding of how 
oxytocin is typically used in the US, including indication, quantification and timing, is not 
readily available. Preventive57,97,111,112 or interventive113–115 measures to decrease excessive use 
or misuse of oxytocin exist, but it is unclear to what extent they have been adopted.  
 Measurement is a persistent difficulty in the study of oxytocin. Many studies use 
“induction” or “augmentation” as variables, but both induction and augmentation are simply 
markers for an array of medications and procedures. When oxytocin is included as an 
independent variable, it is frequently a binary measurement33,35,72–76. Binary measurement of a 
continuous variable means that significant data is lost.  
Recent studies have pioneered different measures, predominantly categorical, to better 
understand oxytocin use and its effects. There has been little methodological conversation, 
however, around the rationale behind these measures and which may be best pharmacologically, 
physiologically, or clinically. Several studies have used “total dose” to measure oxytocin with a 
variety of categorizations to aid interpretation. One key difficulty in summarizing these studies is 
a lack of consistent categorizations of the continuous variable (e.g., comparing percentiles50 of 
oxytocin dose to 5000 mU increases14). Rationales for the categories researchers create are 
frequently not explicitly stated.50 When rationales are given, they focus on choosing total dose 
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categories that the researchers think will result in significant results.36(p56.e5),95(p383) Researchers 
might consider using additional measures of oxytocin exposure that provide more information 
and greater clinical utility than a binary variable. Some examples include: total oxytocin dose 
(mU); maximum infusion rate (mU/min); and total duration (min) of oxytocin exposure. Further 
research is needed to determine the most effective measures of oxytocin exposure.  
While there is some heterogeneity in the findings of these studies – due, in part, to the 
nature of the research questions and binary measurement of oxytocin – the overarching finding is 
that oxytocin exposure is an independent risk factor for postpartum hemorrhage. There is 
evidence that even two hours on a 20 mU/min infusion of oxytocin substantially increases the 
risk of severe postpartum hemorrhage, as does increasing the infusion rate above 20 mU/min 
[ref]. Further research is needed, however, to corroborate these findings, refine the understanding 
of oxytocin’s association with hemorrhage (e.g., arrive at clinically relevant points in oxytocin 
exposure where risk for hemorrhage increases exponentially) and to translate these findings to 
inform clinical practice. One immediate suggestion, however, would be to include the potential 
increased risk for postpartum hemorrhage in providing informed consent to women around 
oxytocin use in labor.  
To better understand the relationship between oxytocin exposure in labor and the risk of 
cesarean section, more detailed information about the use of oxytocin and its timing is needed. 
Since the majority of the extent literature on oxytocin’s association with cesarean section 





While frequent use of oxytocin in the intrapartum is documented in a variety of high-income 
countries, none of them have rates of maternal and neonatal morbidity and mortality as high as 
the United States. This suggests that while overuse or inappropriate use of oxytocin may 
contribute in part to morbidity and mortality outcomes, there are factors beyond its use that play 
a role. More research is needed regarding decision-making and communication around oxytocin 
use in the intrapartum period. Well-delineated definitions and measures are essential and may 
also require further research to develop. 
 Practice changes are needed to shift obstetric culture and how we use oxytocin. Two 
related foci for policy change are using the minimal amount of oxytocin necessary and 
addressing misuse of oxytocin (e.g., augmentation without an indication). Checklists, partograms 
and turning oxytocin off in active labor hold promise as ways to standardize the use of oxytocin, 
thereby improving maternal and neonatal outcomes.41,56,57,97,111–116 Other potential interventions 
include one-on-one support, either with nurses or doulas.117–119 The call for more judicious 
oxytocin use is not new41, but it is time to act.  
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Table 1: Oxytocin Prevalence in Intrapartum Care 
Author (Year) Study Type and Purpose Country & study population  Prevalence of oxytocin use 
Laughon (2012)35 Retrospective cohort study 
(Consortium on Safe Labor) to 
describe labor induction 
(indications, methods and 
delivery mode) in the US 
US (19 hospitals across the 
US); 208,695 women 
42.9% of nulliparous and 
31.8% of multiparous women 
were induced; 35.5% and 
44.1% of these were 
elective35(p486.e1) 
Of those who were induced, at 
minimum 65.8% of nulliparous 
and 62.8% of multiparous 
women were induced with 
oxytocin alone (as the authors 
note, other methods of 
induction may have included 
oxytocin exposure)35(p486.e7) 
Laughon (2012)76 Secondary analysis of two 
retrospective cohorts – 
Collaborative Perinatal Project 
from 1959-1966 and 
Consortium of Safe Labor 
from 2002-2008 
US (CPP 39,491 women and 
CSL 98,359 women) 
Oxytocin augmentation 
increased from 12% to 
31%76(p419.e2) between the two 
cohorts 
Nystedt (2014)84 Retrospective cohort 
examining prevalence, 
management and outcome of 
prolonged labor with normal 
labor 
Sweden; 829 women with 
spontaneous labor84(p1) 
28% were augmented with 
oxytocin without evidence of 
prolonged labor84(p1) 
Petersen (2013)79 Prospective cohort study 
examining sequence of 
interventions with relation to 
length of labor and delivery 
mode 
Lower Saxony, Germany; 
3,055 low-risk women 
delivering in hospitals 
Overall, 40.5% of women were 
augmented with oxytocin 
(52.6% of nulliparous, 27% of 
multiparous women)79(p249) 
“one may infer that oxytocin 
was not always applied 
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appropriately in our study 
population”79(p253) 
Belghiti (2013)77 (in French and English) 
Secondary Data Analysis of 
the French Perinatal Survey 
Data to estimate the frequency 
of oxytocin administration 
during labor – and 
characteristics of woman and 
hospital associated with its use 
France; 14,681 women 64% of laboring women 
received oxytocin in labor; 
58% of women with 
spontaneous labor received 
oxytocin77(p663) 
Factors increasing risk of 
oxytocin exposure: epidural, 
nulliparity, overweight, 
“private status”, small 
maternity unit77(p663) 
Tam (2013)75 Retrospective cohort study 
examining outcomes for 
elective induction of labor 
US; 848 records 73.7% were induced with 
oxytocin as the primary 
agent75(p407); shorter duration of 
labor noted 
Bernitz (2014)82 Secondary data analysis of a 
randomized controlled trial 
examining the effect of 
oxytocin augmentation and 
birth outcomes 
Norway; 747 low-risk 
nulliparous women 
43.8% of the study population 
was augmented with oxytocin; 
42.5% of these women did not 
meet dystocia criteria85(p364) 
Selin (2009)78 Retrospective cohort 
examining use of oxytocin for 
augmentation and association 
with labor progress and 
delivery outcome 
Sweden; 1,263 women at ≥ 37 
weeks gestation in spontaneous 
labor with a single, vertex 
fetus 
55% of women received 
oxytocin (75% of nulliparous, 
38.1% of multiparous); 
oxytocin was used in a 
haphazard manner – women 
were over or under-
treated78(p1353) 
Oxytocin use varies 
significantly by hospital78(p1353) 
Cesareans were related to 
underlying labor dystocia – not 
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oxytocin (suggesting need for 
better decision-making tools) 
Rosenbloom (2017)72 Secondary data analysis of a 
prospective cohort study 
conducted between 2010-2014 
at the Washington University 
School of Medicine to examine 
effect of adopting the 2010 
CSL labor guidelines to reduce 
cesarean 
US; 7,845 women at ≥ 37 
weeks with a vertex, singleton 
pregnancy and no history of 
cesarean 
Oxytocin use varied from 66-
68.3%72(p689.e3) 
Buchanan (2012)83 Retrospective cohort study to 
examine intrapartum oxytocin 
use trends and associations 
with morbidity from 1998 to 
2008 
NSW Australia; 322,640 low-
risk, nulliparous women with 
single, cephalic fetus 
45.4% of women in the study 
were exposed to oxytocin – 
increase was due to increased 
use of induction 
Associated with increased 
maternal and neonatal 
morbidity; as well as epidural 
use, operative and cesarean 
delivery83(p173) 
Neal (2014)57 Secondary data analysis from 
two prospective cohort studies 
conducted in three hospitals in 
the midwestern US to examine 
effect of admission in early 
labor on interventions 
US (Midwest); 216 nulliparous 
women in spontaneous labor 
142 of 216 nulliparous women 
in spontaneous labor received 
oxytocin augmentation74(p31) 
Kjerulff (2017)33 Prospective cohort study of 
women delivering in 
Pennsylvanian hospitals 
between 2009-2011 examining 
risk factors for cesareans 
among nulliparous women 
US (PA); N = 2,851 
nulliparous women with 
vertex, singleton pregnancy 
attempting vaginal birth 
30.1% of women induced with 
oxytocin, 57.3% of women 
augmented with oxytocin33(p7) 
Of 2,851 nulliparous women, 
34.3% were induced – 69% of 




Zhang (2010)73 Secondary data analysis of the 
Consortium of Safe Labor 
Database (retrospective cohort 
study) to examine labor 
patterns in the US 
US; N = 62,415 women “nearly half of the parturients 
included in our analysis were 
given oxytocin for 
augmentation”73(p5) 
Cheyney (2014)120 Retrospective cohort study of 
the Midwives Alliance of 
North America Statistics 
Project to examine outcomes 
(2004-2009) 
US; 16,924 women 4.5% of the total population 
received oxytocin120(p17)  
10.9% were transferred, 22% 
of these required oxytocin 
augmentation120(p22) 
Offerhaus (2014)81 Secondary Data Analysis of 
the Netherlands Perinatal 
Registry to examine the rate of 
cesarean sections and other 
interventions in low-risk births 
(at home and in the hospital) – 
2000-2008 
Netherlands: 807,437 births Of 39,747 nulliparous women 
in 2008, 32.4% were 
augmented; of 48,200 
multiparous women in the 
same year, 7.8% were 
augmented (this was a 
significant increase from 2000 
when 18.9% of 42,787 
nulliparous and 4.5% of 
48,882 multiparous women 
were augmented with 
oxytocin)81(p651) 
In 2008, 45.6% of nulliparous 
women who planned to deliver 
at home delivered in the 
hospital – of these, 19.1% 
received augmentation; 38.7% 
of multiparous women 
transferred, 9.3% of these 
received augmentation81(p652) 
(though it should be noted that 
some women delivering at 
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home also received 
augmentation) 
Halfsdansdottir (2015)80 Matched retrospective cohort 
study to examine outcomes of 
homebirth in Iceland (2005-
2009) 
Iceland; 307 home births to 
921 planned hospital births 
Overall oxytocin augmentation 
was 22% with 8.8% of planned 
home births receiving oxytocin 
and 26.4% of planned hospital 




Table 2: Oxytocin Measurement 
Author (Year) Study type and purpose Country and Study 
Population 
Oxytocin measures Authors’ rationale for 
measure choices 
Grotegut (2018)98 Secondary data analysis 
of a retrospective cohort 
study at Duke (2009-
2010) and a French 
cluster randomized 
controlled trial (2004-
2006) to examine 
whether max rate and 
duration could be a 
surrogate for the total 
dose of oxytocin received 
in labor 
US and France; 402 
and 6,907 women, 
respectively 
-Maximal oxytocin rate 
(mU/min) 
-Total duration (h) 
-Oxytocin product 
(mU/min * min) 
-Oxytocin total dose 
(AUC) (mU) 
*Found significant 
correlation between max 
rate*tot duration and 
“total dose” 
Oxytocin exposure is an 
important predictor of 
labor outcomes98(p79) 
Surrogate for total dose 
that is easier to calculate 
(p 79) 
(Not clear how this would 
be helpful during labor, 
though) 
Roloff (2015)92 Retrospective cohort 
study of women 
delivering from May-July 
2012 in a California 
institution to examine the 
cumulative oxytocin dose 
needed to achieve 
vaginal delivery among 
obese/non-obese women 
US (California); 413 
women 
Total dose of oxytocin 
received in mU 




Secondary data analysis 
of the Maternal-Fetal 
Medicine Units cesarean 
registry (prospective 
cohort) to examine 
whether max infusion 
rate is associated with 
US; 41,941 women 
who experienced 
labor in the MFMU 
cesarean registry 
Max infusion rate 
(mU/min) – max greater 
than 20 mU/min 
significantly associated 
with increased risk for 
atony 
To modify oxytocin 
protocols to reduce max 
rate and thereby reduce 
risk of PPH 




uterine atony as total 
oxytocin exposure 
Carlson (2017)121 Secondary data analysis 




2012 to examine the 
effect of BMI, and other 
factors, on hourly doses 
of oxytocin 
US (Colorado); 400 
women (matched) 
Duration 
Mean oxytocin infusion 
rate - “Rate across entire 
augmentation” 
mU/min24(p388) 
Total dose of oxytocin 
(mU) 
Hourly oxytocin dose 
(mU) – average – and 
then looked at how BMI 
affected this 
Research has not found 
BMI to predict total dose 
of oxy in spontaneously 
laboring women – 
unknown whether BMI 
predicts the hourly 
oxytocin dose121(p383) 
Grotegut (2011)36  Retrospective case-
control study at Duke 
from 2000-2004 to 
compare oxytocin 
exposure in women with 
postpartum hemorrhage 





“area under the oxytocin 
dose curve” defined as 
mu/min * min14(p56.e2) 
Looked at the increased 
OR of PPH over 5000 
mU increases in 
oxytocin14(p56.e5) 
No specific rationale 
given 
Looked at 5000 mU 
increases because this was 
believed to be more likely 
to have meaning clinical 
implications – no 
discussion of why 5000 
mU 
Frey (2015)94  Nested case-control study 
of a retrospective cohort 
study at a tertiary care 
hospital from 2004-2008 
in order to examine 
characteristics associated 
with high maximum 
oxytocin dose 
US (Washington); 
108 cases and 2,864 
controls 
Cases = oxytocin > 20 
mU/min, Controls = 
oxytocin <= 20 mU/min 
(associated factors: 
GDM, LGA, intrapartum 
fever, magnesium, IOL) 
To identify women 
exposed to an oxy rate >= 
20 mU/min to construct 
better oxy 
guidelines94(p1614) 
Mohta (2018)97 Retrospective cohort 
study from 2012-2016 to 
assess the effect of an 
US (California); 
34,612 women 
Initial infusion rate 
Max infusion rate 
Average infusion rate 
To examine effect of 
intervention – which 
decreased oxytocin use on 
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oxytocin checklist on 
usage and outcomes 
Duration all counts – also a 
decrease in NICU 
admissions and neonatal 
oxygen requirements 
Maeder (2017)96 Retrospective cohort 
study from January-June 
2013 to evaluate 
oxytocin titration for 
post-dated induction 





women (21 normal 
weight, 134 





Max infusion, mU/min 
Time between rate 
changes 
Current dosing practices 
come from old studies 
that didn’t look at BMI, 
but recent studies show 
BMI increases oxy dosage 
Belghiti (2011)50 Secondary data analysis 
(nested case-control 
study) of a cluster 
randomized controlled 
trial (Pithagore6) to 
examine the association 
between oxytocin 
exposure in labor and 
risk of severe PPH 
France (2004-2006); 
3,238 (1,483 women 
were cases and 
1,758 women were 
controls) 
Binary 
Total dose (IU) 
Max infusion rate 
(mIU/min) 
Total duration (min) 
Categorized to the 50th, 
75th and 90th percentile 
No specific rationale 





Table 3: Oxytocin and Postpartum Hemorrhage 





Maternal Effects Measurement Dose/Duration 
Associated with 
Outcome 
Bernitz (2014)82 Secondary data 
analysis of a 
randomized 
controlled trial 










dystocia had an 
increased risk of 




“at all three units 
oxytocin, to some 
extent, was given 
without indication” 
(365) 
Active labor was 3-4 
cm (365) 
Odds of PPH stat 
significant for 
augmented but no 
dystocia compared to 
no dystocia and no 
augmentation (366) – 
both results 
disappeared in the full 
model (368) 
Max dose was 30 
mU/min 
Oxytocin measured 
as binary variable 
N/A 
Steinberg (2013)46 Mini-Cochrane 
review of two studies 
to examine whether 
oxytocin 





“Oxytocin does not 









and 93 ≤ 6 cm 
dilation46(p760) 
of cesarean delivery, 
instrumental vaginal 
delivery … no effect 
on postpartum 
hemorrhage”46(p760) 
*Not sure that their 
sample population was 
appropriate, given their 
research question 
Grotegut (2011)36 Retrospective case-
control study at Duke 
from 2000-2004 to 
compare oxytocin 
exposure in women 
with postpartum 
hemorrhage due to 





Oxytocin and PPH 
Case group had mean 
oxytocin AUC of 
10,054 mU, compared 
to mean to 3,762 mU 
in controls (mean 
might not be best 
choice, as oxytocin 
right skewed – median 
a better choice) 
Case and control 
groups not exactly 
equivalent – far more 
pre-eclamptics (and 
more likely to be 
exposed to mag) in 
case group and 
race/ethnicity groups 
differ; also, had lower 
hematocrits36(p56.e3) 
“area under the 
concentration curve” 
(mU/min*min) = 
also total oxytocin 
dose 
Total time of 
infusion 
Time from infusion 
to delivery (min) 
Max oxytocin 
infusion (mU/min) 
Time from max rate 
to delivery (min) 
Oxy dose at delivery 
(mU/min) 
Oxytocin on at 
delivery 




outcome – used 
5000 mU intervals 
 
After adjusting, 
OR was 1.58 and 
stat significant 
(For every 5000 
mU increase, odds 
of severe PPH 
increased by 
58%)36(p56.e5) 
Sosa (2011)100 Secondary data 
analysis of a 
retrospective cohort 







mod/severe PPH or 










transfusion in the 36% 
of women who 
received 
AMTSL87(p238.e1) 
6991 of 11,323 women 
were exposed to 
oxytocin in labor 
(238.e2) 
A lot that was not 
adjusted for in overall 
model (238.e4) 
Ekin (2015)88 Retrospective cohort 
study to identify risk 
factors and etiology 









the odds of severe PPH 
(but about 25% of the 
study population had a 
severe PPH, so not 
sure OR is the best 
method for presenting 
the data) 
No discussion of how 
blood loss was 
measured; used blood 
loss ≥ 2000 mL as 
criteria of severe PPH 
Binary variable N/A 
Bischoff (2017)102 Literature review to 
examine whether 
induction or 
augmentation of labor 
prior to CS increases 
the risk of PPH 
 PPH 
Dearth of research – 
most research looked 







found two studies that 
might provide further 
data, but these were 
not yet completed; 
they also found 2 
studies looking at 
amount of oxytocin 
needed to prevent PPH 
after CS for arrest (10) 
– laboring women 
exposed to intrapartum 
oxytocin may require 
greater doses PP to 
prevent hemorrhage 




Literature review of 
oxytocin 
augmentation and its 
maternal effects 
 
* Beautiful table 
looking at oxytocin 
augmentation and risk 
of PPH (p 517-518) 




and increased risk of 
PPH seen in 
observational studies, 
not RCTs103(p515) – but, 
they conclude that 
“Overall, oxytocin 
administration during 
spontaneous labor is 
associated with a 
higher risk of PPH, 
especially when the 
dose used during labor 
Grotegut and 
Belghiti were the 
studies mentioned 
who measured 
oxytocin in ways 
other than binary; 
also, Loscul et al 
looked at increment 
interval – but this 




is high, the increment 
intervals are short, or 





Mehrabadi (2013)6 Retrospective cohort 
study to examine the 
etiology of the 







PPH (not explained by 
IOL/AOL) 
Not able to explain the 
increase in PPH (had 
labor induction and 
oxytocin augmentation 
data – but not 
complete oxytocin 
data) 

























risk of PPH 
IOL common, but 
OR used to report 
results – maybe not 
best statistical 
method 







study to examine 
labor induction with 
cervical ripening 
(pharm or mech) 
versus oxytocin alone 






ripening increased risk 
greater than oxytocin 
alone – esp. among 
nulliparous women 
Binary 
Results reported as 
percentages; not 
specified if there was 





Grotegut (2015)93  
Poster 
Secondary analysis of 
the MFMU registry to 
examine whether max 
infusion rate was 
associated with 
uterine atony in like 

















study conducted to 
examine incidence of 






augmentation was one 
of the factors with 
highest risk for 
PPH89(p1) 
IOL 19% in 2015; 
Oxytocin AOL 26.2% 
in 2015 
Binary N/A 
Belghiti (2011)50 Secondary data 
analysis (nested case-






oxytocin exposure in 
labor and risk of 








73% of cases and 61% 




higher odds of severe 




** Active labor 
defined as 3 cm 
Binary variable 
Total dose (IU) 
Max infusion rate 
(mIU/min) 
Duration (min) 
Categorized by 50th, 




Odds of severe 
PPH was 3x 
higher for total 
dose 2-4 IU and 
6x higher for total 
dose > 4 IU; odds 
also increased 
with increasing 
max infusion – 2.2 
for max rate of 
10-15 mIU/min 
and 3.2 for max 















Table 4:  Oxytocin and Cesarean Section 











study examining the 
effect of oxytocin 













No effect on 3rd or 4th 
degree lacs (2 women 
total), epis (36 total) 
Of women in 




as binary variable 
N/A 




deliveries in women 
with an epidural 





oxytocin vs not and 
outcomes – however 
the number of women 
in the two studies 
were so limited, more 
studies are required 
(2) 
Outcomes were CS 
and operative 
delivery; interventions 
were oxytocin vs 
expectant management 
Likely binary N/A 
Begley (2014)43 Lit review examining 
outcomes in studies 
examining oxytocin 
 Outcome measures Binary N/A 
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use for treating 
prolonged first or 
second stage 
Bernitz (2014)82 Secondary data 
analysis of a 
randomized 
controlled trial 












dystocia had an 
increased risk of 




“at all three units 
oxytocin, to some 
extent, was given 
without indication” 
(365) 
Active labor was 3-4 
cm (365) 
Odds of CS was stat 
significant (366) – but 
numbers were small 
Max dose was 30 
mU/min 
Oxytocin measured 
as binary variable 
N/A 
Brown (2013)107 Cochrane review to 
examine active 
management of labor 
(oxytocin, 
amniotomy and one-
on-one care) for 
reducing cesarean 
section  




AML associated with 
a small reduction in 










study to examine 
cesarean section rate 





section from 41.6% to 
32.7% - postulate one 
possible reason is that 
Institution of 
oxytocin protocol (1 
mU/min increased 




 implementation of a 
low-dose oxytocin 
policy designed to 
decrease 
liability44(p53) 
non-reassuring FHT is 
one of the main 
indications for CS in 
laboring women – 
tachysystole is a 
common effect of 
oxytocin which might 
lead to NRFHT (53) 
more frequently than 
every 15 min – 








study to examine 
labor induction with 
cervical ripening 
(pharm or mech) 
versus oxytocin alone 





PPH and Cesarean 
Induction with 
ripening increased risk 
greater than oxytocin 
alone – especially 
among nulliparous 
Binary – seems like 
they just looked at 





Rossen (2016)56 Prospective cohort 
study to examine 
implementation of an 
oxytocin protocol and 
whether the protocol 
would change the 
profile of oxytocin 






decreased from 34.9 to 
23.1%56(p355); found 
overall decrease in 
cesareans and 
decrease in cesareans 
for fetal distress56(p355) 
– on p 358, emergency 
cs very labile, not 
clear downward trend 
– also, labor >12 hr 
increased; severe PPH 
incidence increased 
(visually estimated) 
Protocol was 6 
mU/min, increased 
by 3 mU/min every 
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Oxytocin Use and Its Association with Postpartum Hemorrhage and Primary Cesarean 
Section in the US: A Study Protocol 
Introduction 
Oxytocin is a peptide hormone associated with orgasm, labor contractions, milk let-down, social 
bonding and stress reduction.2,122  Centrally, oxytocin is made in the hypothalamus and secreted 
by the pituitary gland; peripherally, it is made by a variety of organs, including the placenta.18,123 
Oxytocin in its synthetic form is commonly used in obstetric practice to induce or augment labor, 
as well as prevent or treat postpartum hemorrhage (PPH). Induction, the stimulation of labor 
prior to its spontaneous onset, is considered when the benefits of delivery outweigh the risks of 
continuing the pregnancy.124 Augmentation is the stimulation of contractions when the presence 
of the same has not resulted in progress in labor, measured by cervical dilation or fetal 
descent.125 
Postpartum hemorrhage is a leading cause of maternal morbidity and mortality.3  While 
maternal mortality rates have decreased globally, severe maternal morbidity has continued to 
increase.126,127 Rates of atonic PPH, the most common type of PPH have increased in a number 
of high-resource countries.4–11  The rate of PPH in the US is estimated to be 2.9%; but it accounts 
for 19.1% of in-hospital deaths after birth and is one of the most common causes of intensive 
care unit admission.10 Morbidity related to PPH is significant and may include outcomes ranging 
from anemia and difficulty breastfeeding to loss of fertility, postpartum depression and post-
traumatic stress disorder.12,13  Observational studies in the United States have found that patient 
risk factors for PPH explain little of the rise in atonic PPH.4,5,8,10,11  Most of these studies have 
used the National Inpatient Sample, which provides demographic data and International 
Classification of Disease (ICD) codes; the ICD, however, does not contain all codes pertinent to 
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PPH risk.5,8,10,11  Specifically, the ICD does not contain codes for labor augmentation and, 
especially, for either induction or augmentation performed with synthetic oxytocin.  Exposure to 
synthetic oxytocin in labor is an established risk factor for atonic PPH14–16 and the extent of 
synthetic oxytocin use in obstetric practice may be increasing.17,18  Oxytocin use is also 
associated with another significant maternal outcome and focus of quality initiatives, the primary 
cesarean section.19–22 
Currently, 32% of births in the United States are cesarean sections.23  Cesarean sections 
are considered major abdominal surgery and the procedure is associated with a number of 
adverse outcomes, including an increased risk for hemorrhage, infection, neonatal respiratory 
distress and complications with future pregnancies.24,25  Reducing primary cesareans in low-risk 
women is a quality indicator for the Center for Medicare and Medicaid Services’ Obstetric Core 
Measures, as well as a Healthy People 2020 goal and an initiative for the American College of 
Nurse-Midwives and the American Congress of Obstetricians and Gynecologists25–28.  Oxytocin 
use is an independent risk factor for cesarean sections.19–22,29 
Background 
While it is estimated that 23% of births in the US are induced, there is evidence that this might 
be an underestimation, with rates of induction closer to 40%.35,128 No billing code exists for 
augmentation, but it is estimated that 24% to 66% of births in the US are augmented.33,35,73 
Induction and augmentation of labor are independent risk factors for PPH.8,30–32 Induction is an 
independent risk factor for primary cesareans.19–22 Oxytocin is commonly used for both 
induction and augmentation and its use is associated with an increased risk of postpartum 
hemorrhage and primary cesarean section.14,16,48,83,85 Induction and augmentation, however, 
cover a wide array of procedures and medications governed by varying policies.33–35 For 
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instance, induction of labor may be performed with mechanical dilators, such as a Foley catheter, 
or with medications, such as methergine. Procedures to augment labor include artificial rupture 
of membranes and oxytocin administration. Although oxytocin is a high-alert medication1 and 
there is evidence that more than half of laboring women in the United States are exposed to 
it33,41,72,75,91, little is known about how it is used. In order to address the high rates of PPH and 
primary cesareans, in order to improve the quality of obstetric care in the United States, in order 
to improve maternal and neonatal outcomes, oxytocin use must be better understood.  
This study examined the use of synthetic oxytocin in obstetric practice and its association 
with postpartum hemorrhage and primary cesarean section by using a nationwide sample of 
hospitals with inpatient obstetric units. To accomplish this purpose, the study: 1a) examined the 
incidence of synthetic oxytocin exposure in women admitted for labor in a large nationwide 
sample of hospitals; 1b) among women who received synthetic oxytocin, described synthetic 
oxytocin exposure via “total dose” by indication, as well as patient-, provider and hospital-level 
variables; 2a) examined the relationship between synthetic oxytocin exposure and postpartum 
hemorrhage accounting for patient-, provider- and hospital-level variables; 2b) for those that 
received synthetic oxytocin, examined the relationship between amount received as measured by 
“total dose” and postpartum hemorrhage accounting for patient-, provider- and hospital-level 
variables; 2b.1) explored whether there is a clinically-relevant point of oxytocin exposure 
associated with the risk of PPH; 3a) examined the relationship between the receipt of synthetic 
oxytocin and unscheduled cesarean accounting for patient-, provider- and hospital-level 
variables; 3b) for those that received synthetic oxytocin, examined the relationship between 
amount received as measured by “total dose” and unscheduled cesarean accounting for patient-, 
provider- and hospital-level variables; and 3b.1) explored whether there is a clinically-relevant 
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point of oxytocin exposure associated with the risk of a primary, unscheduled cesarean section. 
The study’s a priori hypotheses were that: 1) the majority (i.e., > 50%) of hospital labors 
observed would include synthetic oxytocin exposure and the primary use of synthetic oxytocin 
will be for labor augmentation; 2) increased dose and duration of synthetic oxytocin would be 
associated with higher risk of PPH among women treated with this intervention, independent of 
patient characteristics; and 3) oxytocin exposure would be positively associated with the 
occurrence of primary, unscheduled cesarean sections, while accounting for patient-level 
variables. 
Methods 
This study is a secondary data analysis of the Consortium on Safe Labor, a publicly-available 
database housed at the Eunice Kennedy Shriver National Institute of Child Health and Human 
Development.129 
Sample 
Women admitted to the hospital for delivery, who were not admitted for a pre-labor cesarean, 
were considered at-risk for oxytocin exposure and were included in the study. The study sample 
was developed from the Consortium on Safe Labor, which was initially developed to examine 
patterns in labor progression and the etiology of frequent cesareans in the United States.129 The 
study collected a large number of variables, including, but not limited to: maternal 
demographics, maternal medical and obstetric history, current pregnancy information, labor 
progress and outcome, medication administration (especially oxytocin), neonatal data, provider  
and hospital information. Data was collected from 19 hospitals, representing the American 
Congress of Obstetricians and Gynecologists’ nine districts, via medical chart abstraction.129 The 
database includes information about 228,562 births that occurred between 2002-2008.129 Patient 
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information was de-identified before being sent to the Data Coordinating Center and is available 
to researchers upon request.129 
Inclusion and Exclusion Criteria 
Sites were included if they collected oxytocin data. Of the original 12 sites, 9 (75%) collected 
oxytocin data. These nine sites became the overall study sample, for a sample size of 182,742 
births (147,981 unique women). Five sites were ultimately kept in the oxytocin dose data-set, for 
a sample size of 54,456 births (51,639 unique women). Women were excluded from the study if 
they were admitted for a scheduled cesarean since they would, theoretically, not be at-risk for 
oxytocin exposure. Of the 182,742 study participants, 20,541 (11.2%) were excluded for having 
a pre-labor cesarean section. All other women admitted to sites that collected oxytocin data were 
included in the study. 
Sample size and power analysis 
Postpartum hemorrhage incidence, based on ICD-9 codes, is estimated to be 2.9% in the United 
States.130 In the study sample, 3% of the study sample had an ICD-9 code for PPH. Meanwhile, 
3.1% of the study sample received a postpartum blood transfusion (about half of the women in 
the sample are missing data for this variable) and 12.3% of the population had a hemorrhage by 
estimated blood loss and delivery mode (i.e., greater than 500 mL of blood lost in a vaginal 
delivery; greater than 1000 mL of blood lost in a cesarean delivery). 
A power analysis was conducted for the first part of the second aim, examining the 
association between oxytocin exposure in labor and postpartum hemorrhage. Assuming the 
frequency of oxytocin exposure among women admitted for labor is around 50% and that the 
rate of postpartum hemorrhage is 5%, an N of 4000 would be required to have 80% power, given 
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a significance level of 0.05, to detect an odds ratio (OR) of 1.46 for oxytocin as a predictor of 
PPH. Rates of postpartum hemorrhage vary; 5% was based on a sample from Johns Hopkins 
Hospital and is a little higher than some estimates (2.9%)130 and a little lower than others (6-
11%)131. Based on the literature, the adjusted OR (aOR) of 1.52 reported by Khirredine et al.31 
provides the best estimation of the risk of PPH after vaginal delivery given oxytocin exposure; 
the OR is likely to be higher (as evidenced by Al-Zirqi et al.32) if the delivery type is cesarean.   
 An additional power analysis was conducted for the second part of the second aim, 
examining the relationship between specific oxytocin dose exposures and postpartum 
hemorrhage. Oxytocin total dose means and standard deviation for women with and without PPH 
from Grotegut et al.14(p56.e4) were used to estimate the effect size of differing oxytocin dose 
exposures on the outcome of postpartum hemorrhage.  Grotegut et al.14 found a 1.58 increase in 
the odds of PPH for every 5000 mU increase in oxytocin dose. With an N of 2000 and given a 
significance level of 0.05 and a 5% PPH incidence rate in the population, the analyses would 
have 88% power to detect an odds ratio of 1.58 for oxytocin doses as predictors of postpartum 
hemorrhage. 
 Finally, a power analysis was conducted for the third aim, examining the association 
between oxytocin exposure and primary cesarean section. Assuming the frequency of oxytocin 
exposure is 50%41 and that the rate of primary cesareans is 26.9%128 (Zhang et al45 found 
primary cesarean rates of 31.2% for nulliparous and 9.4% for multiparous women in the CSL 
data), an N of 3400 would be required to have 80% power, given a significance level of 0.05, to 
detect an odds ratio of 1.28 for oxytocin as a predictor of unscheduled cesarean sections.  In the 
literature, the adjusted odds ratios for having the outcome of a cesarean, given an induction of 
labor (not, specifically, oxytocin exposure), are commonly greater than 1.32.  Seyb et al.19 
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reports an aOR of 1.89 for elective inductions and 1.69 for medical inductions; Heffner et al.20 
reports an aOR of 1.7 for nulliparous women being induced and 1.49 for multiparous women 
being induced; Yeast et al.21 reports an aOR of 1.75 for induced nulliparous women and 1.31 for 
induced multiparous women; and Caughey et al.22reports an aOR range of 1.33-1.92 for induced 
nulliparous women and 0.76-1.57 for induced multiparous women. There are no data on AUC 
and unscheduled cesarean section in order to conduct a power analysis for Aim 3b. Based on the 
power analyses for each of the specific aims, a minimum sample size of 4000 women is needed. 
The power analysis was conducted on PASS 14.0.132 
Measures 
Oxytocin 
Oxytocin exposure is typically measured as a binary variable; while this is the simplest approach, 
significant information about the exposure is lost. The amount of oxytocin a woman is exposed 
to varies for a variety of reasons related not only to the patient (such as body mass index, 
gestational age and expression of oxytocin receptors2), but the provider and hospital, as well. We 
used total oxytocin dose (the sum of the products of each oxytocin infusion rate multiplied by the 
exposure time, calculated for each individual woman) in milliunits as the primary measure of 
oxytocin, as it captures more information about oxytocin exposure than binary measurement. 
Due to the wide range of oxytocin total dose, and in order to increase clinical utility, an oxytocin 
total dose categorial variable was created based on the continuous variable. The total dose 
categorical variable started at 0 mU and increased by 600 mU increments (equivalent to one hour 
on an infusion of 10 mU/hr) and, in the last few categories, by 1200 mU increments (equivalent 
to one hour on 20 mU/min as fewer women were exposed to these higher doses). The infusion 
rate categorical variable was created based on the maximum oxytocin infusion rate a woman 
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received. The maximum infusion rate categories were based on typical oxytocin policy – 20 
mU/hr and 40 mU/hr – with 10 mU/hr being added in order to assess “low-dose” exposure. The 
binary measure of oxytocin exposure (i.e., yes/no) was used initially to enable comparison the 
study results with other studies that only use a binary measure.14,93 Maximum oxytocin infusion 
rate (mU/min) provided a second measure of oxytocin exposure.16,99 Stratifying women by the 
maximum infusion rate received provides more information than binary measurement and offers 
a simple clinical cross-over if typical protocol maximum infusion rates are used.99 
PPH 
The outcomes variables are postpartum hemorrhage (PPH) and primary cesarean.  Only early 
PPH will be included, as, hemorrhage occurring in the first 24 hours after birth is more common 
and more likely to be associated with an atonic uterus and, hence, oxytocin exposure. Diagnosis 
of postpartum hemorrhage is complicated by inaccuracies in blood loss measurement, which is 
normally estimated visually and tends towards underestimation.  Estimated blood loss may also 
be calculated by weighing or measuring, but both of these methods may be inaccurate due to the 
inclusion of other fluid (e.g., amniotic fluid or urine). Nevertheless, estimated blood loss is 
important because it is the primary method for diagnosing postpartum hemorrhage clinically. 
Hence, postpartum hemorrhage is likely underdiagnosed.  In order to improve the identification 
of PPH, it will be defined in the following ways:  a) postpartum hemorrhage diagnosis code 
(ICD-9 code) will provide the primary diagnosis of PPH; in the absence of a PPH diagnosis 
code, PPH will be diagnosed by:  b) estimated blood loss (mL) with ≥ 500 mL and ≥ 1000 mL 
will indicate a PPH for vaginal or cesarean delivery, respectively and c) transfusion, emergent 
hysterectomy, manual removal of the placenta16, uterine exploration16, postpartum dilation and 
curettage, or use of methylergonivine, misoprostol, or carboprost.  In the absence of estimated 
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blood loss and the presence of one of the above listed scenarios, a hemoglobin change of greater 
than 2 g/dL will be used to diagnose PPH.16   
Cesarean 
Cesarean section will be identified by ICD-9 code and recorded as a binary variable (yes/no). 
Women presenting for a scheduled cesarean (whether primary or repeat) are excluded from the 
study sample, therefore, cesarean deliveries in the study sample are ostensibly unplanned and 
represent either a primary cesarean or a failed trial of labor after a previous cesarean. The 
relationship between oxytocin total dose and primary cesarean sections will also be assessed.  
Maternal Variables 
Race/ethnicity, age, gestational age, parity and body mass index were collected from the labor 
and delivery admission form, as well as reproductive or medical history forms. Antenatal “large 
for gestational age” status was collected from the participant’s prenatal history. Chronic and 
gestational diabetes, gestational hypertension, superimposed preeclampsia, severe and moderate 
eclampsia and eclampsia were all derived from the participants’ charts. Chronic hypertension 
was based on an ICD-9 code and chart data, while magnesium sulfate and fever were both 
collected from the labor and delivery summary. Further detail about how variables were derived 
was not available. All of the maternal condition variables were binary. Race/ethnicity was 
categorical and included the following categories: White, non-Hispanic; Black, non-Hispanic, 
Hispanic, Asian/Pacific-Islander, Multi-racial and Other. Age, gestational age, parity and body 
mass index were all continuous variables. 
Provider and Hospital Variables 
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Provider type (physician, midwife, physician-midwife team) was collected from the attending 
provider information on the delivery note. Hospital type, either teaching university, teaching 
community or non-teaching community hospital, was controlled for as an independent variable. 
Site was also controlled for. Site was the health system that participated in and contributed data 
to the Consortium on Safe Labor. Most sites only included one hospital (which varied by type), 
but one site included two different kinds of hospitals. Site likely represents system-specific 
policies and practice culture. 
Recruitment and Data Collection 
This was a secondary analysis of the Consortium on Safe Labor database. Data for the original 
study was extracted from electronic medical records by participating sites and recorded on a data 
extraction form.133 Data extraction was coordinated by the “Data Coordinating Center” (DCC) 
which provided retrieval and transfer support.133 Patient identifiers were removed prior to data 
transfer, except for dates which were re-coded by the DCC.133 After data was transferred, the 
DCC prepared the database for analysis, including running audits on charts selected by an 
algorithm which sampled randomly and identified critical records requiring closer query.133 
 Most of the variables were collected in one central database, but oxytocin dosing and 
cervical exams for individual study participants were recorded in two separate databases. For the 
purpose of this study, the oxytocin database was merged with the central database by matching 
the participant identification number and entry number, since some women entered the study 
multiple times with subsequent pregnancies. 
Analysis Plan 
The demographic profile of the study sample was summarized with mean and standard deviation, 
frequencies and percentages, or median and interquartile range, depending on the distribution of 
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the variable. Descriptive statistics will also be provided for the Sites included in the study 
sample. Data will be examined for significant outliers. Statistical significance will be set at p < 
0.05.  
To examine the incidence of oxytocin exposure, overall incidence and the corresponding 
95% Confidence Interval (CI) was presented.  Exposure was then presented in terms of 
indication (induction vs. augmentation), patient, provider and hospital characteristics via 
incidence and corresponding 95% CI.  Among women who received oxytocin, exposure was 
described by total dose, maximum infusion rate (by category and continuous) and time in hours 
and reported as median and interquartile range (IQR), stratified by indication, patient 
characteristics and hospital type. Patient characteristics included:  indication (induction; 
augmentation), patient age (<20, 20-34; ≥35), race (non-Hispanic white/Caucasian; non-
Hispanic Black/African-American; Hispanic; Asian/Pacific Islander), BMI (<18.5; 18.5-24.9; 
25-29.9; 30-34.9, 35-39.9; ≥ 40), gestational age in weeks (<360; 360-376; 380-416; ≥420) and 
parity (0; 1-4; ≥5).   
Multivariable logistic regression was used to examine the relationship between the 
receipt of oxytocin and postpartum hemorrhage accounting for patient-, provider- and hospital-
level variables. Clustering of women was managed by controlling for site. Participant entry, as 
some women re-entered the study with subsequent pregnancies, was also controlled for to handle 
the violation of the assumption of independence of observations, since women could enter the 
study more than once. Oxytocin exposure was initially measured as a continuous variable and 
then as a categorical variable (total dose categories and maximum infusion rates). PPH was 
outcome predicted by oxytocin, age, race, parity, gestational age, body mass index, gestational 
diabetes, diabetes, chronic hypertension, gestational hypertension, hypertension with super-
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imposed pre-eclampsia, mild pre-eclampsia, severe pre-eclampsia, eclampsia, magnesium 
therapy36(p56.e4), labor dystocia, delivery mode, multiple pregnancy, macrosomia, maternal fever, 
entry into the study, provider-type, hospital-type and site number. Exploratory analyses were 
conducted to examine various thresholds of oxytocin exposure for association with PPH. A 
logistic regression was run with an oxytocin dose categorical variable; oxytocin dose categories 
increased by 600 mU (representing exposure to 10 mU/min for one hour) until the last 3 
categories which increased by 1200 mU. After the regression was run, categories that were 
statistically significantly associated with increased odds of postpartum hemorrhage (and 
statistically different from each other) were used as oxytocin dose categories representing 
thresholds of increased risk. The same set of analyses, excluding delivery mode, was used to 
examine the relationship between the receipt of synthetic oxytocin and primary cesarean section.  
Finally, the regression model was used to predict the probability of oxytocin exposure, 
and of postpartum hemorrhage and primary cesarean, in the study sample, while controlling for 
potential confounding variables as listed above. 
Missing Data 
Within the oxytocin data set, observations were dropped if the time variable was negative, 
missing or “0”, which resulted in a sample size of 78,217 from 78,571. If the time variable was 
negative, it indicated postpartum oxytocin exposure, which was not of interest for the study. If 
the time variable equaled 0, 89.95% of the time, the dose variable was 0 or missing. Dealing with 
missing time was a challenge, due to the exceedingly wide range of exposure times, however, 
there was no reliable way to impute this time. 42% of the oxytocin doses associated with missing 
time were also missing (listed as “6666” or “9999”). There were 6,133 valid oxytocin doses, 
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ranging from 0-36 mU/min, associated with a missing time and all of these were from Sites 48 
and 49. 
Nine hospitals collected any oxytocin data and were included in the overall sample (see 
Figure 3). Of the nine sites, four were dropped. Three were dropped for having no oxytocin 
doses and one was dropped because 91% of the oxytocin doses were missing. Of the five 
remaining sites, one was missing 70% of the oxytocin doses, another was missing 17% and the 
remaining three were missing 2% or less of the oxytocin doses. Unknown oxytocin doses 
resulted in the observation being dropped as, again, there was no reliable way to impute these 
numbers.  
In the sample, of all of the variables used in the model, only four were missing data. 
Those four variables were provider type (791 missing data), BMI (1,837 missing data), maternal 
age (200 missing data) and parity (1 missing datum). Among the sub-sample of women with 
recorded oxytocin doses, there were 34 missing data for provider type, 734 missing data for BMI 
and 8 for maternal age. In addition, there were 543 missing oxytocin total dose data; this is likely 
due to participants missing an oxytocin dose or time. Stata Statistical Software: Release 15 was 
used to conduct statistical analyses of the data.134 
Sensitivity Analysis 
Sensitivity analyses were conducted to examine the effect of changing the definition of 
postpartum hemorrhage on the outcome of the regression. Two different regression models were 
run, replacing PPH as identified by ICD-9 code with estimated blood loss at birth and postpartum 
transfusion status. In a similar manner, three different measures of oxytocin exposure were used 
as the dependent variable in the regression model – binary (yes/no exposure to oxytocin), total 




This study significantly advanced the measurement of one of the most powerful – and common – 
medications used in labor. Categories of oxytocin total dose exposure in this study were smaller 
than in other studies and were created to be translatable for clinical understanding (i.e., 
categories were based on a 10 mU/min infusion rate over an hour). This study is innovative in its 
use of predicted probability to interpret the regression models.135 Oxytocin’s dose-specific 
association with primary cesarean section has not been previously studied, so this research 
provides preliminary findings for an aspect of obstetric care that is the subject of many quality 
improvement initiatives. At least two other studies examine oxytocin dosing in relation to the 
outcome of postpartum hemorrhage.14,16 This study corroborates the dose-association of oxytocin 
with PPH (e.g., the risk of PPH seems to increase around 5000-6000 mU of oxytocin exposure), 
as well as an infusion-rate association.14,16 Birth outcomes are complex, with numerous factors at 
play; this research will inform future studies to refine the measurement of oxytocin (including 
during its use in “real time”) and the understanding of its many effects to change how it is used 
and improve maternal health care and outcomes.  
While the analysis plan was created prior to receiving the Consortium on Safe Labor 
data, significant adjustments were made after receiving the data set, based on the available 
information and upon further consideration of statistical methods. Since the prevalence of 
oxytocin exposure and primary cesarean section are high, the odds ratio does not approximate 
relative risk well.136 Odds ratios are also not easy to interpret.137 Predicted probabilities based on 
the regression models were created to better understand and approximate the risk of the 
outcomes of interest.135 
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One of the biggest challenges was the measurement of oxytocin. The initial plan was to 
analyze oxytocin dose as a continuous variable. When the analysis was conducted, the large 
range of doses and the positive skew of the distribution rendered the analysis difficult to 
interpret. By looking at total dose over hour increments, points where the probability of 
hemorrhage or cesarean increased significantly were noted. Total oxytocin dose is a newer 
method of measurement14,16 and one that holds promise for understanding clinically relevant 
points of exposure to oxytocin as it relates to potential adverse outcomes.  The use of total dose 
in this research will not only allow a more nuanced understanding of oxytocin’s effect on 
important measures of morbidity and quality care but will also contribute to the science 
regarding the use of this method for future research. 
Presence of an ICD-9 code for postpartum hemorrhage was the primary indicator of 
hemorrhage. Estimated blood loss at birth, measured continuously in milliliters, was used to 
analyze the sensitivity of the hemorrhage definition. Other potential markers of hemorrhage, 
such as postpartum hemoglobin or receiving postpartum uterotonics apart from oxytocin, were 
not available in the data set. A variable for transfusion was available, though data was missing on 
more than half of the sample. Discrepancies in the data set indicated problems with the clinical 
diagnosis of hemorrhage. For instance, most women who received a postpartum blood 
transfusion were documented as losing less than 500 mL in a vaginal birth. Despite these 
difficulties, the use of three different definitions of hemorrhage and the use of sensitivity 
analyses is fairly detailed and similar to the triangulation methods used in other studies15,16.  
As in any study, and especially in a secondary data analysis, missing data was a concern. 
Initially, the plan was to examine the data (specifically, the oxytocin data) for patterns of 
“missing-ness” and then, potentially, to drop missing observations. While this is a relatively 
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unrefined method of dealing with missing data, and one that might be a source of unaccounted 
bias, substituting an “average” would have skewed the results of the analyses. Per the power 
analysis, despite dropping missing observations, there was still a sufficient sample size to 
examine the events of interest. Further, relatively little oxytocin data was missing from the five 
sites that were eventually included in the oxytocin analysis. Despite this, bias is still a concern. 
Women who were missing data were not noted to be systematically different on a patient-level, 
but the fact that only certain sites contributed oxytocin data and that these sites were different 
from each other (see Appendix 1) might contribute bias to the results. 
Limitations 
The study involves the secondary analysis of the Consortium on Safe Labor (CSL) database; as 
such, the collection of the research was not informed by this study’s specific research question 
and the data was not collected by the authors. As a result, while the CSL contains most of the 
variables of interest, there were some pertinent variables (e.g., diagnosis of labor dystocia) that 
were not available for analysis. A related example is that not all the variables which were 
intended to help define which women sustained a postpartum hemorrhage were available, such as 
postpartum hemoglobin. The sensitivity analyses that were run as part of the study, however, 
helped confirm that most women with a postpartum hemorrhage were captured. A similar issue 
occurred with a measure which indicated whether a woman had a pre-labor cesarean. The 
variable was not a perfect marker for a pre-labor cesarean, however, as some women who were 
marked as having a pre-labor cesarean were also noted to have labored or received oxytocin prior 
to their cesarean. The decision was made to use the pre-labor cesarean variable as a marker, 
however, in order to remain consistent with the data codebook.  
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It is possible that multiple definitions of labor were used if this was not clearly defined 
from the beginning of the study. Another limitation was significant amounts of missing data, 
especially in the oxytocin data set, and the difficulty of imputing missing oxytocin data; despite 
this, the sample was still large when compared with similar studies14,16, and more than met the 
power analysis criteria. 
The original Consortium on Safe Labor (CSL) data set is large and contains a wealth of 
information. The data, however, was collected from 2002-2008. In 2009 the American College 
of Obstetricians and Gynecologists (ACOG) updated their induction of labor guidelines 
(reaffirmed in 2016).124 As a result of these guidelines, elective inductions of labor prior to 39 
weeks gestation have decreased in the United States, resulting in a concern that the CSL data 
might not reflect current usage of oxytocin usage. In the study sample, 103,617/162,201 women 
were missing data as to whether they received an elective induction. 15,229 women (9.4% of 
study sample) had elective inductions of labor; of these, 13.7% were induced prior to 39 weeks. 
While the number of elective inductions at less than 39 weeks may be lower today, the overall 
exposure to oxytocin in labor in this sample is consistent with other data from the US, Europe 
and Australia. Furthermore, ACOG’s policy around dystocia and augmentation has not changed 
since 2003.125 The recommendations around oxytocin infusion rates, provided in both the 
induction and augmentation policy, have not changed, either.124,125 Therefore, despite the age of 
the data set, the prevalence is likely still reflective of current obstetric practice. As oxytocin 
infusion protocols have not changed, the age of the data set should not affect the association of 
oxytocin dose to postpartum hemorrhage and primary cesarean section. Prospective research 





This is a large study using de-identified, publicly available data, to examine a significant factor 
in maternal morbidity and poor-quality outcomes in obstetric care. The study uses a novel 
approach to examine oxytocin use, as well as clinically-significant points in oxytocin exposure, 
to develop awareness of oxytocin over-use, offer insight into more appropriate use for the 













Oxytocin in US obstetric practice and its association with postpartum hemorrhage and 
primary cesarean section: A Secondary data analysis of the Consortium on Safe Labor 
Introduction 
Oxytocin is the hormone associated with orgasm, labor contractions, milk let-down and social 
bonding.2 Oxytocin in its synthetic form is commonly used in obstetric practice to induce or 
augment labor, as well as prevent or treat postpartum hemorrhage (PPH). Postpartum 
hemorrhage is a leading cause of maternal morbidity and mortality.3 While maternal mortality 
rates have decreased globally, rates of atonic PPH, the most common type of PPH, have 
increased in a number of high-resource countries (e.g., Australia, Canada, Ireland, US, UK).4–11 
Morbidity related to PPH is significant and may include outcomes ranging from anemia and 
difficulty breastfeeding to loss of fertility, postpartum depression and post-traumatic stress 
disorder.12,13 Observational studies in the United States have found that patient risk factors for 
PPH explain little of the rise in atonic PPH.4,5,8,10,11 Most of these studies have used the National 
Inpatient Sample, which provides demographic data and International Classification of Disease 
(ICD) codes; the ICD, however, does not contain all codes pertinent to PPH risk.5,8,10,11 
Importantly, the ICD does not contain codes for labor augmentation, or for the induction of labor 
with oxytocin. Oxytocin exposure in labor is an established risk factor for atonic PPH15,16,36, as 
well as primary cesarean section under certain conditions, and its use in obstetric practice may be 
increasing.17,18  
The reduction of primary cesarean sections is the focus of multiple quality intiatives.19–22 
Currently, 32% of births in the United States are cesarean sections.23  These are major abdominal 
surgeries associated with a number of adverse outcomes including an increased risk for 
hemorrhage, infection, neonatal respiratory distress and complications with future 
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pregnancies.24,25  Reducing primary cesareans in low-risk women is a quality indicator for the 
Center for Medicare and Medicaid Services’ Obstetric Core Measures, as well as a Healthy 
People 2020 goal and an initiative for the American College of Nurse-Midwives and the 
American Congress of Obstetricians and Gynecologists25–28.  Oxytocin use is an independent risk 
factor for cesarean sections.19–22,29 
Background 
Labor induction and augmentation can be achieved with a variety of medications and procedures, 
but the use of synthetic oxytocin is most common. Induction and augmentation are both 
independent risk factors for PPH.8,30–32 In addition, induction or augmentation (especially in 
latent or early labor) of nulliparous women increases the risk of a primary cesarean section.25 
Yet, the incidence of oxytocin exposure and the dose of medication to which laboring women are 
exposed in not well understood, despite the fact that oxytocin could account for some of the risks 
associated with induction and augmentation.   
Oxytocin is the drug commonly used for both induction and augmentation, and its use in 
labor may explain much of the increase in atonic PPH in high-resource countries.15 Similarly, 
labor induction is an independent risk factor for primary cesareans, with oxytocin being the 
medication commonly used for induction.19–22 Induction and augmentation rates in obstetric 
practice in the United States are high, but both terms cover a wide array of procedures (e.g., 
mechanical induction with cervical dilators to augmentation with artificial rupture of membranes 
to the use of oxytocin).33–35 The incidence and character of oxytocin exposure in laboring women 
in hospitals in the United States is unknown. Oxytocin is a high-risk medication1 and it is 
possible that its use is the main reason why induction and augmentation are independent risk 
factors for PPH and primary cesareans.  
42 
 
In order to address the high rates of PPH and primary cesareans, in order to improve the 
quality of obstetric care in the United States, in order to improve maternal and neonatal 
outcomes, oxytocin use must be better understood. To this end, the purpose of this study is to 
examine the use of synthetic oxytocin in obstetric practice in the US, and its association with 
postpartum hemorrhage and primary cesarean section, by using a nationwide sample of hospitals 
with inpatient obstetric units. To accomplish this purpose, the study will: 1a) examine the 
incidence of synthetic oxytocin exposure in women admitted for labor; 1b) to describe synthetic 
oxytocin exposure via “total dose” by indication, as well as patient-, provider and hospital-level 
variables; 2a) examine the relationship between synthetic oxytocin exposure and postpartum 
hemorrhage accounting for patient-, provider- and hospital-level variables; 2b) examine the 
relationship between amount received as measured by “total dose” and postpartum hemorrhage 
accounting for patient-, provider- and hospital-level variables; 2b.1) explore whether there is a 
clinically-relevant point of oxytocin exposure associated with the risk of PPH; 3a) examine the 
relationship between the receipt of synthetic oxytocin and unscheduled cesarean accounting for 
patient-, provider- and hospital-level variables; 3b) examine the relationship between amount 
received as measured by “total dose” and unscheduled cesarean accounting for patient-, 
provider- and hospital-level variables; and 3b.1) explore whether there is a clinically-relevant 
point of oxytocin exposure associated with the risk of a primary, unscheduled cesarean section. 
The study’s a priori hypotheses were that: 1) the majority (i.e., > 50%) of hospital labors 
observed will include synthetic oxytocin exposure and the primary use of synthetic oxytocin will 
be for labor augmentation; 2) increased dose and duration of synthetic oxytocin will be 
associated with higher risk of PPH among women treated with this intervention, independent of 
patient characteristics; and 3) oxytocin exposure will be positively associated with the 
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occurrence of primary, unscheduled cesarean sections, while accounting for patient-level 
variables. 
Methods 
Data from the Consortium on Safe Labor data (CSL), a publicly-available database housed at the 
Eunice Kennedy Shriver National Institute of Child Health and Human Development, was 
performed to address the specific aims.129 The CSL was initially developed to examine patterns 
in labor progression and the etiology of frequent cesareans in the United States.129 Data were 
collected from 19 hospitals, representing the American Congress of Obstetricians and 
Gynecologists’ nine districts, via medical chart abstraction which was coordinated by the Data 
Coordinating Center.129 The database included 228,562 births between 2002-2008.129 Patient 
information was de-identified before being sent to the Data Coordinating Center and is made 
available to researchers upon request.129 
Study Sample 
This study is a secondary data analysis of the Consortium on Safe Labor Database from the 
National Institute of Health. The analytic sample (see Figure 1) consisted of data from women 
admitted for delivery at 9 of 12 study sites that collected any oxytocin data; women were 
excluded from analysis if admitted for a pre-labor cesarean section. A total of 162,201 births 
were included in the final analytic sample; these were births at sites that collected any oxytocin 
data to women who had not undergone a pre-labor cesarean. A 2nd analytic sample included only 
study participants whose oxytocin doses administered were collected, comprised of 54,456 births 





Oxytocin exposure in the overall sample was defined as 1) entry into the oxytocin data set or 2) 
documented oxytocin induction or augmentation. This definition was created because not all 
women who received oxytocin in labor were included in the oxytocin sub-sample during data 
collection. The binary measure of oxytocin exposure (i.e., yes/no) was used to examine overall 
prevalence in the study sample.14,93 The primary measure of oxytocin exposure was total 
oxytocin dose (the sum of the products of each oxytocin infusion rate multiplied by the exposure 
time, calculated for each individual woman, mU) and categorized by 600 mU increments up to 
9600 mU after which categories increased to 1200 mU. Categorization was based on the total 
dose of one hour at a 10 mU/min infusion. The rationale in creating these categories was to have 
small increases that were clinically understandable. The secondary measure of oxytocin exposure 
was the maximum infusion rate (mU/min) a woman received and categorized as ≤ 10 mU/min, > 
10 and ≤ 20 mU/min, > 20 and ≤ 40 mU/min and > 40 mU/min. These categories were created 
based on clinical relevance as most oxytocin policies have a maximum dose of 20 mU/min or, 
less frequently, 40 mU/min.16,99  
Postpartum Hemorrhage 
The outcomes of interest were postpartum hemorrhage (PPH) and primary cesarean section.  
Only early PPH was included, since hemorrhage occurring in the first 24 hours after birth is 
more common and more likely to be associated with an atonic uterus and, hence, oxytocin 
exposure. Diagnosis of postpartum hemorrhage is complicated by inaccuracies in blood loss 
measurement, which is typically a visual estimate.  Numerous studies have found that visually 
estimated blood loss is inaccurate and tends towards underestimation.138–140  Hence, postpartum 
hemorrhage is likely underdiagnosed.  In order to improve the identification of PPH, postpartum 
hemorrhage diagnosis code (ICD-9) was the primary operational definition. Alternate operational 
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definitions of PPH, estimated blood loss (≥ 500 mL for a vaginal delivery, ≥ 1000 mL for a 
cesarean delivery) and postpartum transfusion, were then used to conduct sensitivity analyses.  
Cesarean 
Cesarean section was a binary variable based on the labor and delivery summary. 
Maternal Variables 
Race/ethnicity, age, gestational age, parity and body mass index were collected from the labor 
and delivery admission form, as well as reproductive or medical history forms. Antenatal “large 
for gestational age” status was collected from the participant’s prenatal history. Chronic and 
gestational diabetes, gestational hypertension, superimposed preeclampsia, severe and 
moderate eclampsia and eclampsia were all derived from the participants’ charts. Chronic 
hypertension was based on an ICD-9 code and chart data, while magnesium sulfate and fever 
were both collected from the labor and delivery summary. Further detail about how variables 
were derived was not available. All of the maternal condition variables were binary. 
Race/ethnicity was categorical and included the following categories: White, non-Hispanic; 
Black, non-Hispanic, Hispanic, Asian/Pacific-Islander, Multi-racial and Other. Age (<20, 20-34; 
≥35), gestational age (<360; 360-377; 380-416; ≥420), parity (0; 1-4; ≥5) and body mass index 
(<18.5; 18.5-24.9; 25-29.9; 30-34.9, 35-39.9; ≥ 40) were all categorical variables. Entry into the 
study was also controlled for, since some women re-entered the study with a subsequent 
pregnancy. 
Provider and Hospital Variables 
Provider type (physician, midwife, physician-midwife team) was collected from the attending 
provider information on the delivery note. Hospital type, either teaching university, teaching 




The demographic profile of the study sample was summarized with mean and standard deviation, 
frequencies and percentages, or median and interquartile range, depending on the distribution of 
the variable. Statistical significance was set at p < 0.05.  
Prevalence oxytocin exposure was examined.  Exposure was presented in terms of 
indication (induction vs. augmentation), patient, provider and hospital characteristics.  Among 
women who received oxytocin, exposure was described by total dose, maximum infusion rate 
(by category and continuous) and time in hours and reported as median and interquartile range 
(IQR), stratified by indication, patient characteristics and hospital type. 
Multivariable logistic regression was used to examine the relationship between the 
receipt of oxytocin and postpartum hemorrhage accounting for patient-, provider- and hospital-
level variables. Oxytocin exposure was initially measured as a binary variable, then as oxytocin 
total dose and maximum infusion rate category. PPH, defined by ICD-9 code, was the outcome 
predicted by oxytocin, age, race, parity, gestational age, body mass index, gestational diabetes, 
diabetes, chronic hypertension, gestational hypertension, hypertension with super-imposed pre-
eclampsia, mild pre-eclampsia, severe pre-eclampsia, eclampsia, magnesium therapy36(p56.e4), 
labor dystocia, delivery mode, multiple pregnancy, macrosomia, maternal fever, entry into the 
study (to control for women who entered the study more than once), provider-type and hospital-
type. Exploratory analyses were performed to examine if a certain amount of oxytocin exposure 
was associated with PPH. Predicted probabilities of PPH at different categories of oxytocin 
exposure were created based on the logistic regression model.  As some women re-entered the 
study for subsequent pregnancies, a random sample was created where each woman was selected 
once (which entry was selected was random) and the logistic regression model was then re-run. 
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To further understand the effect of the sites on the associations of interest, the logistic 
regressions were also run stratified by site. 
Multivariable logistic regression was used to examine the relationship between oxytocin 
exposure and primary cesarean section accounting for patient-, provider- and hospital-level 
variables. Oxytocin exposure was initially measured as a binary variable, then as oxytocin total 
dose and maximum infusion rate category. Primary cesarean was the outcome predicted by 
oxytocin, age, race, parity, gestational age, body mass index, gestational diabetes, diabetes, 
chronic hypertension, gestational hypertension, hypertension with super-imposed pre-eclampsia, 
mild pre-eclampsia, severe pre-eclampsia, eclampsia, magnesium therapy36(p56.e4), labor dystocia, 
multiple pregnancy, macrosomia, maternal fever, entry into the study (to control for women who 
entered the study more than once), provider-type and hospital-type. Exploratory analyses were 
conducted to examine if a certain amount of oxytocin exposure was associated with unscheduled 
cesarean section. Exploratory analyses will examine if a certain amount of oxytocin exposure is 
associated with a primary cesarean. Predicted probabilities of primary cesarean at different 
categories of oxytocin exposure were created based on the logistic regression model. Predicted 
probability of primary cesarean section with maternal race as the primary independent variable 
was also examined. As some women re-entered the study for subsequent pregnancies, a random 
sample was created where each woman was selected once (which entry was selected was 
random) and the logistic regression model was then re-run. To further understand the effect of 
the sites on the associations of interest, the logistic regressions were also run stratified by site. 
Missing Data 
Three sites (43, 47 and 51) from the CSL database were not included in the study sample as they 
did not collect oxytocin information. Sites 43 and 51 were both university teaching hospitals, 
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while Site 47 was a community teaching hospital. The sample size ranged from 18,392 women 
for Site 51 to 12,637 women for Site 43. Site 43’s sample was 54.2% black and 30% Hispanic 
while Sites 47 and 51 were 58% and 55.3% white, respectively. Combined, these three sites had 
45,695 women with a mean parity of 0.97 and mean gestational age of 38.6 weeks. Women from 
these three sites ranged in age from 12-58 with a mean age of 29.1 years and had a mean BMI of 
25.3 kg/m2. Most of the women from these sites were missing data on education level, but 60.8% 
of the women were married and 42.9% had private insurance (30.8% had public insurance). 
There were more black and Hispanic women in the sample from the three sites than in the study 
sample. Compared to the study sample, women from the three sites had a lower mean parity and 
a higher mean age. 
20,541 women were excluded from the study sample due to having a pre-labor cesarean 
section. These women were more likely to be black (28.4%) or Hispanic (21.1%) compared to 
the overall study sample. Mean parity for the women with a pre-labor cesarean was 1.36 and the 
mean gestational age was 37.3 weeks. Mean age and mean BMI were 29.8 and 27.8 kg/m2, 
respectively, which is both older and heaver than the overall study sample. 
In the study sample, oxytocin dose data were only collected for some of the women. 
Demographic data was examined to understand some of the overall differences between the 
women in the oxytocin dose sub-sample and the women for women no oxytocin dose data was 
collected. Women in the study sample, but not the oxytocin dose sub-sample, were 48.5% white, 
21.1% black and 17.5% Hispanic with a mean age of 27.2 years and a mean BMI of 25.1 kg/m2. 
They had a mean parity of 1.2 children and a mean gestational age of 38.5 weeks. The most 
remarkable difference between the two groups of women was the difference in racial/ethnic 
make-up of the groups (61.5% white in the oxytocin dose group vs. 48.5% white in the no 
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oxytocin dose group), though the other demographic categories were statistically significantly 
different. 
1,374 (2.5%) women were dropped from the oxytocin-PPH model due to missing data. 
This missing data were predominantly missing BMI (734), following by a missing oxytocin dose 
category (543), with 34 women missing provider-type and 8 missing age. 1,295 (2.4%) women 
were dropped from the oxytocin-primary cesarean model due to missing data. This missing data 
were predominantly missing BMI (734), oxytocin dose category (543) and age (8). 
Results 
Sample Demographics 
The study sample consisted of 162,201 women (some of whom reentered the study with 
subsequent pregnancies). The sample was 52.8% white, 20.1% black and 16.3% Hispanic with a 
mean parity of 1.16, mean age of 27.25 years, mean BMI of 25.3 kg/m2 and a mean gestational 
age of 38.6 weeks. 41.1% of the study population was nulliparous, while 55.9% had 1-4 children. 
77.7% of the women in the study ranged in age from 20-34. The BMIs of women in the study 
were concentrated in the normal range of 18.5-24.9 kg/m2 and in the obese category of ≥ 40 
kg/m2 at 35.3% and 36.7%, respectively. 52.5% of women in the study had a gestational age of 
39-40.6 weeks, followed by 27.9% of women between 37-38.6 weeks. For a more detailed 
description of the sample demographics, please see Table 5. 
Specific Aim 1 
The first specific aim was to examine the incidence of synthetic oxytocin exposure in women 
admitted for labor and then, in the oxytocin subset, to describe synthetic oxytocin exposure via 
“total dose” by indication, as well as patient-, provider and hospital-level variables. The sample 
included 162,201 births from nine different hospitals. Of these, 106,958 (65.9%) were exposed to 
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oxytocin. 31,614 (19.5%) women were marked as being induced with oxytocin, while 54,654 
women (33.7%) were marked as being augmented with oxytocin. Oxytocin dosing data was 
available for 54,456 women in the study sample. 19.6% of the 162,201 births ended in a cesarean 
section, 73.1% of which were primary cesarean sections. 
Due to variation in the data collected at different sites, the nine sites which had collected 
any oxytocin data were included in the sample. Of the nine sites, only five sites (41, 42, 44, 46 
and 52) collected specific oxytocin doses. Sites 42, 44 and 49 were predominantly Black-serving 
(see Appendix 1); Sites 41, 45, 46, 50 and 52 were predominantly White serving and Site 48 was 
predominantly Hispanic serving (53.4% Hispanic; 29.5% Black). All sites, except 50, reported a 
greater than 50% oxytocin exposure rate; Site 50 (67.4% White, 13.6% Asian/PI) reported at 
48% oxytocin exposure rate. The two sites with the greatest exposure rates were 44 and 48 at 
99.96 and 89%, respectively. In terms of predominantly white-serving hospitals, three of them 
reported that less than 10% of patients were black; sites 46 and 52 reported a patient population 
32.5 and 25.4% black, respectively. 
Overall, the probability of being exposed to oxytocin during labor in the overall sample, 
while controlling for age, parity, gestational age, body mass index, site and study entry was 
65.9% (SD 17.2%). The sample for this model may be seen in Figure 5. When the model was 
expanded to control for maternal conditions (chronic diabetes, gestational diabetes, chronic 
hypertension, gestational hypertension, preeclampsia superimposed on chronic hypertension, 
mild preeclampsia, severe preeclampsia, eclampsia, magnesium sulfate exposure, macrosomia 
and intrapartum fever), provider and hospital type, site, entry, race and labor length, the 
predicted probability of being exposed to oxytocin was 65.98% (SD 18.5%). 
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The oxytocin subset was used to describe synthetic oxytocin exposure via “total dose” by 
indication, as well as patient-, provider and hospital-level variable. Total dose ranged from 1 – 
108,000,000 mU; 860 mU was the 25th percentile, 2618 mU was the 50th percentile, 5936 mU 
was the 75th percentile, 15,114 mU was the 95th percentile and 26,977 mU marked the 99th 
percentile (see Table 9). Total time of oxytocin exposure ranged from 0.02 to 943,841 hours; 3.8, 
6.1, 9.4, 17.2 and 29.7 hours marked the 25th, 50th, 75th, 95th and 99th percentiles, respectively. 
The maximum oxytocin infusion rate ranged from 1-1200 mU/min; 7, 12, 20, 30 and 40 mU/min 
marked the 25th, 50th, 75th, 95th and 99th percentiles, respectively. Figure 1 describes the exposure 
of total oxytocin dose in greater detail; 20.3% of births were exposed to 0-600 mU of oxytocin, 
10.9% of births were exposed to 600-1200 mU of oxytocin and 4.1% of births were exposed to 
15,000-27,000 mU of oxytocin. From a different perspective, 44.1% of births involved a 
maximum oxytocin infusion rate of ≤ 10 mU/min, 42.3% of births involved a maximum oxytocin 
infusion rate of between 10-≤20 mU/min, 13.4% of births were exposed to an oxytocin infusion 
rate of 20-≤40 mU/min and 0.2% (115) births were exposed to an oxytocin infusion rate > 40 
mU/min. 
Oxytocin exposure increased after 41 weeks gestational age and with body mass index > 
25 kg/m2 (though it decreased slightly for body mass index > 40 kg/m2); oxytocin exposure 
decreased with increasing parity and maternal age. Oxytocin exposure was increased for Black 
and Hispanic women, compared to White, non-Hispanic women (see Table 10). Significant data 
was missing for the indication for oxytocin exposure (induction or augmentation); 20.6% of the 
women in the study sample were marked as being augmented with oxytocin, but 61% of women 
are missing data on whether they received augmentation. 37.2% of women in the study were 
induced, 19.5% of women were induced with oxytocin specifically and, of these, 9.1% were 
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augmented with oxytocin as well. The probability of oxytocin exposure is decreased when the 
birth attendant is a midwife (59.8%) compared to a physician (67.9%), controlling for all other 
variables. Oxytocin exposure was less likely at a University-affiliated teaching hospital (59.2%) 
compared to a teaching community hospital (68%) but was similar to the 59.4% probability of 
oxytocin exposure at a non-teaching community hospital. Despite the pattern in the raw numbers, 
when controlling for confounders, the probability of oxytocin exposure was greatest for Asian/PI 
women (71.2%), followed by White, non-Hispanic women (66.7%) and then Black, non-
Hispanic and Hispanic women (64.1 and 64.2%, respectively). The reason for this change is 
controlling for the Site, suggesting that the delivery site plays an integral role in oxytocin 
exposure. These findings are similar to those reported by Nippita et al.141 regarding the role of 
provider and hospital culture in induction. This finding also agrees with other studies which have 
found that the hospital itself plays a critical role in racial differences noted in labor management 
and outcomes.142–144 Similar to the pattern seen in the raw numbers, the probability of oxytocin 
exposure increases with body mass index > 25 kg/m2 but decreases with a body mass index > 40 
kg/m2. 
Specific Aim 2 
The second specific aim examined the relationship between oxytocin exposure and postpartum 
hemorrhage accounting for patient-, provider- and hospital-level variables in the study sample. 
Then, using the oxytocin subset, the relationship between “total dose” and postpartum 
hemorrhage was examined accounting for patient-, provider- and hospital-level variables and the 
data was examined for points in exposure where risk of hemorrhage increased significantly. The 
probability of postpartum hemorrhage was 2.9% in the study sample, controlling for 
confounders. In raw numbers, the incidence of postpartum hemorrhage (ICD-9) was also 2.9%. 
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Any oxytocin exposure (as compared to none) increased the odds of a postpartum hemorrhage 
(ICD-9) by 1.2 (1.09-1.31). In the oxytocin subset, the incidence of postpartum hemorrhage 
(ICD-9) is 3.21%. Figure 6 presents the sample for the oxytocin-postpartum hemorrhage 
regression. Variables controlled for in the model included maternal characteristics (age, parity, 
gestational age, body mass index and race), maternal conditions (chronic diabetes, gestational 
diabetes, chronic hypertension, gestational hypertension, preeclampsia superimposed on chronic 
hypertension, mild preeclampsia, severe preeclampsia, eclampsia, magnesium sulfate exposure, 
macrosomia and intrapartum fever), provider and hospital type, study entry, labor length and 
mode of delivery. Hispanic (37% increase compared to white) or Asian/Pacific Islander (34% 
compared to white) race/ethnicity statistically significantly increased the odds of a PPH.    
When examining categories of oxytocin total dose (mU), 6000 mU (roughly equivalent to 
receiving a 20 mU/min infusion of oxytocin for less than 5 hours) was the first point where the 
probability of postpartum hemorrhage was statistically significantly greater than the probability 
of PPH with no oxytocin exposure, all other variables held constant (see Figure 8). After running 
several different models, the decision was made to keep 6000 mU and 15000 mU as statistically, 
and potentially, clinically, significant points of oxytocin exposure (see Figure 9). With these “cut 
points”, the model reported a statistically significant 75% increase in the odds of PPH (ICD-9) at 
6000-15000 mU of oxytocin exposure, compared to less than 6000 mU of exposure and a 148% 
increase in the odds of PPH (ICD-9) with an oxytocin exposure of 15000-27000 mU, all other 
variables being held constant (sample 51,372). The probability of having a PPH (ICD-9) 
increased from 2.6% in those receiving less than 6000 mU of oxytocin (compared to 2.9% in the 
overall population) to 4.5% in the 6000-15000 mU category and 6.1% in the 15000-27000 mU 
category, all of which were statistically significant and statistically significantly different from 
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each other (see Figure 4). There were 41,021 births exposed to ≤ 6000 mU of oxytocin, 10,673 
exposed to 6000-15,000 mU and 2,219 exposed to 15000-27000 mU.  
This model was then re-run, stratifying by parity. The probability of postpartum 
hemorrhage for nulliparous women increased from 2.8% (2.5-3% 95% CI) to 5.2% (4.6-5.8%) to 
6.8% (5.5-8.1%) for 0-6,000, 6,000-15,000 and 15,000-27,000 mU of oxytocin exposure, 
respectively. Multiparous women with 1-4 children had a probability of postpartum hemorrhage 
that increased from 2.4% (2.2-2.6%) to 3.5% (3-4.1%) to 5.4% (3.5-7.3%) for the same three 
categories of oxytocin exposure. Multiparous women with greater than or equal to 5 children had 
the greatest probability of postpartum hemorrhage, starting with a probability of 4.6% (3.3-5.9%) 
at 0-6000 mU, then increasing to 6.6% (2.2-10.95%) at 6,000-15,000 mU and 16% (1.9-30.2%) 
at 15,000-27,000 mU. All of these probabilities were statistically significant. 
When the model was re-run using a random sample (for women who entered the study 
more than once, one of the entries was randomly selected), the probability of postpartum 
hemorrhage went from 2.6% (2.5-2.8% 95% CI) at 0-6,000 mU to 4.3% (3.9-4.7%) at 6,000-
15,000 mU to 6.3% (5.3-7.3%) at 15,000-27,000 mU. This same random sample was then used 
to run the model stratified by site (see Table 8), which shows the shift in the odds of postpartum 
hemorrhage by oxytocin total dose category by site, controlling for the other variables in the 
model. 
The second model conceptualized oxytocin exposure by infusion categories. Compared to 
having a maximum oxytocin infusion rate of ≤ 10 mU/min (24,011 births), every other category 
statistically significantly increased the odds of a PPH (ICD-9), all other variables held constant 
(see Figure 10). Receiving a maximum infusion of ≤ 20 mU/min (23,010 births) increased the 
odds by 45%, ≤ 40 mU/min (7,320 births) by 116% and > 40 mU/min by 451% (only 115 
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women in the sample, however, received an oxytocin infusion > 40 mU/min). The probability of 
having a PPH (ICD-9), given a maximum infusion ≤ 10 mU/min was 2.6% (compared to 2.9% in 
the overall study sample), it increased to 3.7%, 5.4% and 12.3% in the ≤ 20 mU/min, ≤ 40 
mU/min and > 40 mU/min groups, respectively, all other variables being held constant.  
 Two different sensitivity analyses were run to identify whether incidence of postpartum 
hemorrhage had been well-captured. Postpartum hemorrhage was defined first by estimated 
blood loss and, secondly, by postpartum transfusion. In the sample, most blood transfusions were 
received by women who were recorded as losing less than 500 mL of blood after giving birth, 
which suggests something of the difficulty of determining the true incidence of postpartum 
hemorrhage. 19,527 of 54,456 births were missing estimated blood loss information. 27,825 
births involved < 500 mL blood loss, 5,966 births 500-1000 mL, 898 births 1000-1500 mL and 
240 births > 1500 mL. As oxytocin exposure increased, the probability of remaining in the < 500 
mL blood loss group decreased, and, for the other three categories, the probability of being in 
that category increased with oxytocin exposure in a statistically significant manner (see Figure 
11). For example, the probability of losing 500-1000 mL of blood, all other variables held 
constant, is 16% if oxytocin exposure is less than 6000 mU, increases to 18.3% with 6000-15000 
mU and then to 19.4% with 15000-27000 mU. Again, the probability of losing 1000-1500 mL of 
blood, all other variables held constant, is 2% if oxytocin exposure is less than 6000 mU but 
increases to 2.8% is exposure is 6000-15000 mU and increases again to 3.2% if exposure is 
15000-27000 mU. Estimated blood loss, typically a visual measure, is well-documented as 
underestimating actual blood loss. This sensitivity analysis supports the association of increased 
blood loss with increased oxytocin exposure.  
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 The same pattern may be seen with maximum oxytocin infusion (mU/min) as the 
independent variable of interest (see Figure 12). All other variables held constant, as the 
maximum oxytocin infusion rate increases, the probability of inclusion in the < 500 mL blood 
loss group decreases and the probability of inclusion in any of the three other groups increases. 
For example, the probability of losing 500-1000 mL, if one’s maximum infusion rate is ≤ 10 
mU/min is 16%, increasing to 17.1%, 19% and 22.9% for maximum rates of 20, 40 and > 40 
mU/min, respectively. 
 The total dose of oxytocin exposure (mU) does not statistically significantly increase the 
odds of postpartum transfusion. Receiving a maximum oxytocin infusion rate of > 20 mU/min 
and ≤ 40 mU/min (6,344 births), compared to a rate of ≤ 10 mU/min, does statistically 
significantly increase the odds of a postpartum blood transfusion, all other variables held 
constant, by 21%. The probability of receiving a transfusion increases from 6.1% to 7.3%. 
Specific Aim 3 
The third specific aim examined the relationship between the receipt of oxytocin and 
unscheduled cesarean accounting for patient-, provider- and hospital-level variables. Then the 
relationship between amount received as measured by “total dose” and unscheduled cesarean 
was examined using the oxytocin subset, accounting for patient-, provider- and hospital-level 
variables. The oxytocin subset was explored to discover whether there was a clinically-relevant 
point of oxytocin exposure associated with the risk of a primary, unscheduled cesarean section. 
In the overall sample model (80,304 births), controlling for confounders, the probability 
of a primary cesarean is 11.8%. In the entire sample of 162,201 births, 14.3% of births ended in a 
primary cesarean (overall cesarean rate of 19.6%, significantly below the national average). 
From a different perspective, 72.9% of primary cesareans were preceded by oxytocin exposure; 
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67.4% of vaginal births (not including vaginal birth after cesarean or assisted deliveries) were 
preceded by oxytocin exposure. In the oxytocin subset, 12.9% ended in primary cesarean and 
0.6% were repeat cesareans. Figure 7 presents the primary cesarean model sample. Any oxytocin 
exposure increases the odds of a primary cesarean section by 71.4%, compared to no oxytocin 
exposure, all other variables being held constant. Due to the common nature of cesarean sections, 
the odds ratio does not approximate the risk well. Variables controlled for in the model included 
maternal characteristics (age, parity, gestational age, body mass index and race), maternal 
conditions (chronic diabetes, gestational diabetes, chronic hypertension, gestational 
hypertension, preeclampsia superimposed on chronic hypertension, mild preeclampsia, severe 
preeclampsia, eclampsia, magnesium sulfate exposure, macrosomia and intrapartum fever), 
provider and hospital type, study entry and labor length. Black (compared to white) 
race/ethnicity statistically significantly increased the odds (by 39.6%) of having a primary 
cesarean.   
In determining doses of oxytocin exposure that statistically significantly increased the 
probability of primary cesarean section the “mchange” table was examined. Figure 10 shows the 
margin plot displaying probability of primary cesarean section given changing category of 
oxytocin total dose exposure. A small, though statistically significant, decrease in primary 
cesarean section was noted with total doses varying from 600-3600 mU, compared to less than 
600 mU (see Figure 13). After this, the probability of primary cesarean increased with total 
oxytocin dose; increased probability was noted particularly at 4200, 7800 and 12,000 mU (see 
Figure 14). 4200 mU is equivalent to three and a half hours on an oxytocin infusion of 20 
mU/min; at the same infusion rate, 7800 mU is six and half hours and 12000 mU is ten hours. 
Due to titration, women would reach the 4,200-mU mark sooner than three and a half hours. 
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These three exposure points are statistically significantly different from each other and from zero 
(p = 0.000). With an oxytocin exposure ranging from 0-4200 mU, the probability of a primary 
cesarean section is 10.7%. The probability of a primary cesarean with an oxytocin total dose 
ranging from 4200-7800 mU, 7800-12000 mU and 12,000-27,000 mU is 12.7, 16.7 and 21.7%, 
respectively (all statistically significant), all other variables held constant and based on a sample 
of 51,0262 births.  
This model was then re-run, stratifying by parity. The probability of a primary cesarean 
for nulliparous women increased from 19.3% to 23.4% to 28.9% to 34.8% for 0-4,200, 4,200-
7,800, 7,800-12,000 and 12,000 to 27,000 mU of oxytocin exposure, respectively. Multiparous 
women with 1-4 children had a probability of primary cesarean section that increased from 4.1% 
to 4.1% to 6.6% to 10.5% for the same four categories of oxytocin exposure. Multiparous 
women with greater than or equal to 5 children had a probability of primary cesarean section that 
started with a probability of 3.8% at 0-4,200 mU, increasing to 4.6% at 4,200-7,800 mU, 8% at 
7,800-12,000 mU and 16.1% at 12,000-27,000 mU. All of these probabilities were statistically 
significant. 
When the model was re-run using a random sample (for women who entered the study 
more than once, one of the entries was randomly selected), the probability of primary cesarean 
went from 10.96% (10.61-11.3% 95% CI) at 0-4,200 mU to 13.1% (12.45-13.8%) at 4,200-7,800 
mU to 17.62% (16.65-18.59%) at 7,800-12,000 mU to 22.55% (21.4-23.69%) at 12,000-27,000 
mU. This same random sample was then used to run the model stratified by site (see Table 9), 
                                                          
2 For the three primary cesarean models, the oxytocin subset of 54,456 births was the sample. Differences in the 
births included in each model are due to births being dropped by the model due to missing data. 
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which shows the shift in the odds of primary cesarean section by oxytocin total dose category by 
site, controlling for the other variables in the model. 
 In the second primary cesarean model (51,455 births), oxytocin was conceptualized as the 
maximum infusion rate (mU/min). A maximum infusion rate of ≤ 10 mU/min was not 
statistically significantly different compared to >10 - ≤ 20 mU/min with regards to the prediction 
of the probability of a cesarean, so the two groups were combined. The probability of a primary 
cesarean, all other variables held constant, was 11.6% for births in the ≤ 20 mU/min group and 
20.3% in the > 20 mU/min group.  
While not an initial aspect of the study aims, the difference between racial/ethnic groups 
with regards to the probability of a primary cesarean, especially for black women, was striking 
(see Figure 15). The sample size was 51,026 births. The probability of a primary cesarean 
section, all other variables in the model held constant, was 11.4% for white women, 13.77% for 
Asian/Pacific-Islander women, 13.97% for Hispanic women and 16.1% for Black women. There 
were only 1,502 Asian/Pacific-Islander women in the sample; the probability of primary 
cesarean section for each racial/ethnic group was statistically significantly different from each 
other, except Hispanic and Asian/Pacific-Islander women. 
The model was then re-run with an interaction term for the relationship between 
race/ethnicity and oxytocin dose category. When oxytocin total dose ranged from 0-4200 mU 
during labor, white women had a 9.69% probability of a primary cesarean section while black 
women had a 15.9% probability. Exposure to 4200-7800 mU of oxytocin increased the 
probability of a primary cesarean to 11.97% while the probability for black women remained that 
same at 15.9%. From 7800-12000 mU of oxytocin exposure, white women had a 16.2% and 
black women had a 19.66% probability of a primary cesarean section. Finally, an oxytocin total 
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dose from 12,000-27,000 mU was associated with a 21.19% and a 25.07% probability of a 
primary cesarean section for white and black women, respectively. 
Discussion 
This study is unique in specifically purposing to characterize the use of oxytocin in labor in the 
United States. It also significantly advanced the measurement of one of the most common, and 
powerful, medications used in labor. It is one of a few studies to examine oxytocin exposure as a 
continuous variable. It is unique in its pharmacoepidemiologic approach to examining oxytocin 
use, and oxytocin’s dose-specific association with primary cesarean section. At least two other 
studies examine oxytocin dosing in relation to the outcome of postpartum hemorrhage.14,16 This 
study is unique in examining the data for clinically relevant points of oxytocin exposure as 
suggested by small increments in total dose. Specifically, this study found that the probability of 
any oxytocin exposure in this sample was 65.9%. Receiving a total dose of oxytocin greater than 
6000 mU or 4200 mU statistically significantly increased the risk for a postpartum hemorrhage 
or primary cesarean, respectively. Furthermore, having a maximum infusion rate ≥ 10 mU/hr 
significantly increased the risk for a postpartum hemorrhage, while a maximum infusion ≥ 20 
mU/hr significantly increased the risk of a primary cesarean. 
Oxytocin exposure is typically measured as a binary variable, even though it’s a 
continuous exposure. In order to refine the measurement of oxytocin exposure, two studies 
conducted in 2011 introduced continuous measurement of oxytocin exposure via “total dose”16 
or “area under the curve”36. As a continuous measurement, total dose is difficult to interpret, so 
both studies created a categorical variable based on total dose. Belghiti et al50. used the 50th, 75th 
and 90th percentiles to create total dose categories; Grotegut et al.36 examined total dose in 5000 
mU increments. Grotegut et al. noted that they believed that categories in 5000 mU increment 
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would have more significant clinical implications than 1 mU increments or creating a binary 
variable based on total dose.36(p56.e5) In addition to total dose, Belghiti et al.50 examined oxytocin 
as a binary variable and in terms of maximum infusion rate (mU/min) and total duration of 
exposure (min). In 2015, three studies used different methods to measure oxytocin exposure: 
total dose (mU)92, maximum infusion rate (mU/min)93 and a comparison of maximum infusion 
rate at greater or less than and equal to 20 mU/min94. Both studies93,94 that looked at rate did so 
in order to gather information to improve oxytocin protocols; none gave specific rationale behind 
the measurement method chosen. Two 2017 studies used a variety of methods for measuring 
oxytocin exposure: mean and maximum oxytocin infusion rate (mU/min), hourly and total 
oxytocin dose (IU and mU)95 and the duration of each specific infusion rate as well as total 
duration (min) of oxytocin exposure (min)96. In 2018, two studies97,98 used a variety of methods 
to measure oxytocin exposure. One study examined initial, average and maximum infusion rate, 
as well as duration, to examine the impact of instituting an oxytocin checklist on usage and 
outcomes.97 The other study used maximum oxytocin rate (mU/min), total duration (h), oxytocin 
product (mU/min*h [sic]) and total dose (mU) in order to determine whether the product of 
maximum rate times total duration would be a good surrogate for total dose.98(p79) The present 
study has advanced the science by examining small intervals of oxytocin total dose and 
providing a rationale so that future studies may expand upon it.  
While controlling for maternal conditions and characteristics, provider and hospital type, 
site, entry and labor length, the predicted probability of oxytocin exposure during labor was 
65.98% (SD 18.5%), based on a sample of 159,394 births. Median total dose in the sample was 
2618 mU while 5936 mU marked the 75th percentile and 15,114 mU marked the 95th. A total 
dose of 2618 mU equates to roughly a 20 mU/min infusion for two hours. The median total time 
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of exposure was 6.1 hours, with 9.4 and 17.2 hours marking the 75th and 95th percentiles, 
respectively. Both total dose and total time of oxytocin exposure had an exceedingly wide range. 
Maximum oxytocin infusion rate had a median of 12 mU/min; 30 and 40 mU/min marked the 
75th and 95th percentiles. 
Oxytocin exposure is an independent risk factor for postpartum hemorrhage, accounting 
for patient, provider, hospital-level variables. This study advanced the science by examining the 
oxytocin dose and its association with postpartum hemorrhage. The probability of a postpartum 
hemorrhage in the study sample was 2.9% which decreased slightly to 2.6% among women who 
received less than 6000 mU of oxytocin and then increased to 4.5% in women who received 
6000-15000 mU and 6.1% in women who received 15000-27000 mU. The 6000 mU exposure 
point is not so different from the 5000 mU point identified by Grotegut et al.14 The probability of 
postpartum hemorrhage increased significantly with each maximum infusion rate over 10 
mU/min. These findings corroborate two other studies which found that maximum infusion rates 
> 10 mU/min16 and > 20 mU/min14 increased the odds of postpartum hemorrhage secondary to 
uterine atony. 
Oxytocin exposure as a risk factor for postpartum hemorrhage has been demonstrated in 
other studies. These studies, however, frequently operationalize exposure as a binary variable or 
use “induction” or “augmentation”, variables which include a range of medications and 
procedures. A few studies have conceptualized oxytocin exposure in labor as “total dose” or 
“maximum infusion rate” while examining the outcome of postpartum hemorrhage.14,16,99 In the 
two studies which used total dose, categories of oxytocin exposure were created at 5000 mU 
increments14 or by percentiles present in the data16; while both studies found increased oxytocin 
exposure increased the odds of a postpartum hemorrhage, the categories were large or based on a 
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specific data set, thereby making comparisons from future studies difficult. Smaller categories 
based on clinical utility were used in this study to better understand when, in terms of dose and 
time, the probability of a postpartum hemorrhage due to oxytocin exposure increased 
significantly. The probability of a postpartum hemorrhage in the study sample was 2.9% which 
decreased slightly to 2.6% among women who received less than 6000 mU of oxytocin and then 
increased to 4.5% in women who received 6000-15000 mU and 6.1% in women who received 
15000-27000 mU. The 6000 mU exposure point is not so different from the 5000 mU point 
identified by Grotegut et al.14 The probability of postpartum hemorrhage increased significantly 
with each maximum infusion rate over 10 mU/min. These findings corroborate two other studies 
which found that maximum infusion rates > 10 mU/min16 and > 20 mU/min14 increased the odds 
of postpartum hemorrhage secondary to uterine atony. 
In the oxytocin subset of the study sample, the probability of a primary cesarean section 
increased significantly beyond a 4200-mU oxytocin exposure (roughly equivalent to 3.5 hours on 
a 20 mU/min infusion). The probability of a primary cesarean section, all other variables held 
constant, started at 10.7% for women exposed to less than 4200 mU of oxytocin and increased to 
12.7, 16.7 and 21.7% at 4200, 7800 and 12000 mU, respectively. The probability of a primary 
cesarean, all other variables held constant, was 11.6% for births in the ≤ 20 mU/min group and 
20.3% in the > 20 mU/min group. Exposure to any oxytocin, all other variables being held the 
same, increases the probability of having a primary cesarean section significantly, though only 
by 1.2% (overall, the probability of having a primary cesarean given any oxytocin exposure is 
15.5%, compared to a 14.3% probability with no oxytocin exposure). It is possible that this 
different would have been greater if the cesarean section rate in the study sample was closer to 
the national average. Zhang et al.45 reported an overall cesarean rate of 30.5% in the full 
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Consortium on Safe Labor data and noted that half of the cesareans for dystocia were performed 
before 6 cm dilation (i.e., before active labor). 
 Prior to this study, an examination of oxytocin’s dose-association with primary cesarean 
section was not available in the literature. Race/ethnicity was also found to significantly 
influence the probability of having a primary cesarean, all other variables held constant. 
Compared to White women, for whom the probability of a primary cesarean was 11.4%, the 
probability of a primary cesarean for Black women was 16.1%, while for Asian/PI and Hispanic 
women, the probability was 13.77 and 13.97%, respectively. These findings agree with those of a 
number of other researchers who have found that Black women are disproportionately more 
likely to receive a primary cesarean section.145–149 Black women in this sample were more likely 
to receive a cesarean section for non-reassuring fetal tones; these findings agree with several 
other studies.146,147,149 
 Several recommendations are suggested by this research and related studies. Tracking the 
total oxytocin dose a woman has received may improve both health care team communication, 
clinical decision-making and risk assessment for the laboring woman. Specifically, awareness of 
the total dose received may help providers better understand the increasing nature of the risk the 
women in their care are being exposed to – and to discuss those risks with women and mitigate 
them to the best of their ability. This might be especially useful where multiple providers care for 
a woman over a number of shifts to improve communication and decision-making. Providers 
might also consider discussing the increased probability of hemorrhage and primary cesarean 
section as part of their informed consent discussion around oxytocin. Further, providers in charge 
of practice protocols might also reconsider oxytocin infusion protocols that go beyond 20 
mU/min. Other studies have examined checklists97,111,112, partograms150 and interventions such as 
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stopping oxytocin once a woman is in active labor113,151, as means to reduce oxytocin use and 
primary cesarean section with encouraging outcomes. In the national effort to reduce primary 
cesarean sections, we might do well to pay attention to decreasing unnecessary primary cesarean 
sections for Black women. Further research is needed to better understand why Black women are 
more likely to undergo cesarean section for non-reassuring fetal heart tone. 
Strengths 
This study has numerous strengths. The sample was a large one drawn from sites around the 
country. This is the first study to specifically examine the prevalence and characteristics of 
oxytocin use in hospitals from different parts of the country. The sample population was large 
enough to meet the study’s specific aims of examining the dose-association of oxytocin with 
postpartum hemorrhage and primary cesarean section. This study also used smaller categories of 
oxytocin total dose in order to gain a more finally detailed understanding of the drug’s 
association with the outcomes of interest. While using more finally delineated categories of 
oxytocin total dose, this research also corroborates other research conducted in the US36,93 and 
France16 regarding oxytocin’s dose-association with postpartum hemorrhage. This study also 
examined the association of oxytocin dose with primary cesarean section, which has not been 
presented in the literature previously. Finally, this study corroborates the findings of other 
researchers that there are racial disparities in the primary cesarean section rate, with black 
women more likely to undergo the procedure – and to undergo it for non-reassuring fetal heart 
tones – than white women.145,146,152 
Limitations 
The study faced a number of limitations. This was a secondary data analysis, so the original data 
was not collected to address this study’s specific research questions. Due to the nature of the 
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study, it was difficult to address problematic missing data and variable definitions were not 
always clear all of which increased the probability of different kinds of bias. Bias was addressed, 
in part, by having a data analysis plan prior to beginning the study, triangulating variable 
definitions where possible and running sensitivity analyses. One variable that posed difficulty 
was pre-labor cesarean (n=20,541), which, ostensibly, identified women who had a pre-labor 
cesarean delivery. These women were to be excluded from the study, per the analysis plan, as 
they would not be at-risk for intrapartum oxytocin exposure. Upon examining the raw data, 
however, some of the women marked as having a pre-labor cesarean also appeared to have 
labored. This difficulty was addressed by also excluding these women from the study, in order to 
remain consistent with the original study’s coding. If anything, this would make the probabilities 
reported in this study more conservative. The three sociodemographic variables collected for the 
study (education, insurance and marital status) had a lot of missing data. While some research 
has included sociodemographic variables in models examining maternal outcomes, one recent 
nation-wide study found that race/ethnicity was the most important factor, and this variable was 
included in the models.153  
The original Consortium on Safe Labor sample was chosen and weighted to be 
representative of the US as a whole45(p326.e10). For this study, a different study sample was created 
from the original one and is not necessarily representative. For instance, the cesarean section rate 
is far lower in this study sample than in the original (and in the US as a whole) and the 
racial/ethnic make-up of the study sample also varies somewhat. The indication for oxytocin 
augmentation was missing for a significant portion of the study population, limiting what can be 
understood from the study about rationale for oxytocin use in labor. Further, no variables were 
collected by the original study to capture communication or clinical decision-making which are 
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critical components of oxytocin use. While care should be taken, then, in generalizing the results 
of this study, it is still a large sample drawn from sites around the country and offers insight into 
oxytocin use. Further research, especially prospective studies that are generalizable to the wider 
US population, account for indication for oxytocin use, timing of administration (i.e., in active 
versus latent labor), and clinical decision-making around oxytocin use will help further clarify 
how oxytocin is being used and its effects on maternal and neonatal outcomes and satisfaction 
with care. Despite the shift in sample make-up, the sample population was sufficient to examine 
the study’s specific aims regarding the nature of oxytocin use and its association with postpartum 
hemorrhage and primary cesarean section.  
Conclusion 
Oxytocin is a life-saving, but high-alert, medication used in more than half of the labors in the 
United States. If practice in other high-income countries is similar to US practice, it is likely that 
oxytocin is frequently used without a medical indication, especially for labor augmentation. 
Specific oxytocin total doses and infusion rates are associated with a greater risk of postpartum 
hemorrhage and primary cesarean section. The way oxytocin is currently used in US obstetrics is 
tied to many factors, patient, provider and hospital. It will take a culture-change in obstetrical 
care to shift how we use oxytocin, but such change is possible. Oxytocin use is tied to maternal 
morbidity and quality outcomes, but its use, while frequent in other high-resource countries, is 
not associated with the same degree of adverse maternal and neonatal outcomes as we see here in 
the US. Oxytocin is just a piece in a much larger jigsaw puzzle, but a critical piece and one 
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Table 6: Postpartum Hemorrhage Model (n = 51,372; n = 50,335 for random sample)  
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Table 8: Postpartum Hemorrhage Model, stratified by Site  
* Site 41 was missing any data on antenatal large for gestational age, so this variable was dropped from the model. In addition, 
only 6 women from the site were marked as having eclampsia. This variable was also removed from the model. 
** Both of these categories were empty due to collinearity. 
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*Model dropped the three observations in this category. 
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Figure 6: Postpartum Hemorrhage Model Sample  
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Figure 8: Probability of PPH based on Oxytocin Total Dose (mU) 
Figure 9: Probability of PPH based on Oxytocin Total Dose (mU), below  
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 Figure 14: Probability of Primary Cesarean Section by Oxytocin Total Dose (mU) 
 

































Table 9: Oxytocin total dose categories 
 
 
Table 10: Maximum Oxytocin Infusion Rate by Maternal Race/Ethnicity 
  
      Total       53,913      100.00
                                                
      15000        2,219        4.12      100.00
      12000        1,760        3.26       95.88
      10800        1,029        1.91       92.62
       9600        1,296        2.40       90.71
       9000          744        1.38       88.31
       8400          882        1.64       86.93
       7800        1,065        1.98       85.29
       7200        1,147        2.13       83.32
       6600        1,280        2.37       81.19
       6000        1,470        2.73       78.81
       5400        1,703        3.16       76.09
       4800        1,944        3.61       72.93
       4200        2,291        4.25       69.32
       3600        2,693        5.00       65.07
       3000        3,089        5.73       60.08
       2400        3,445        6.39       54.35
       1800        4,179        7.75       47.96
       1200        4,887        9.06       40.21
        600        5,859       10.87       31.14
          0       10,931       20.28       20.28
                                                
    oxy_cat        Freq.     Percent        Cum.
                         100.00     100.00     100.00     100.00     100.00     100.00      100.00 
                          63.48      18.83      14.35       2.85       0.09       0.41      100.00 
              Total      33,459      9,924      7,563      1,502         47        216      52,711 
                                                                                                  
                           0.16       0.33       0.29       0.40       0.00       0.00        0.21 
                          46.02      29.20      19.47       5.31       0.00       0.00      100.00 
        > 40 mu/min          52         33         22          6          0          0         113 
                                                                                                  
                           8.89      25.62      18.66      16.71       6.38      11.11       13.67 
                          41.27      35.29      19.58       3.48       0.04       0.33      100.00 
> 20 & <= 40 mu/min       2,974      2,543      1,411        251          3         24       7,206 
                                                                                                  
                          46.99      29.12      38.32      37.55      25.53      33.80       42.04 
                          70.95      13.04      13.08       2.55       0.05       0.33      100.00 
> 10 & <= 20 mu/min      15,724      2,890      2,898        564         12         73      22,161 
                                                                                                  
                          43.96      44.92      42.73      45.34      68.09      55.09       44.07 
                          63.32      19.19      13.91       2.93       0.14       0.51      100.00 
       <= 10 mu/min      14,709      4,458      3,232        681         32        119      23,231 
                                                                                                  
       oxy_dose_cat   white/non  black/non   Hispanic  Asian/Pac  Mutl-raci      other       Total
                                                 momrace_new
                     
  column percentage  
   row percentage    
      frequency      
                     
  Key                




Oxytocin is a high-alert medication because it is the obstetric drug most commonly associated 
with preventable adverse outcomes.1,57(p32) Oxytocin is a key ingredient in half of all paid 
obstetric litigation claims.57(p33),108 It is also a life-saving medication. So, what are appropriate 
rates of oxytocin use? In low-to-moderate risk women, the need for oxytocin use may be as low 
as 4.5 to 8.8%.80(p21),120(p17) The World Health Organization reports augmentation is needed in 
less than 30% of labors110(pS270). In contrast, most women in the US and in other high-resource 
countries are exposed to oxytocin during labor. Studies from several European countries 
concluded that oxytocin is frequently used without an indication. Preventive57,97,111,112 or 
interventive113–115 measures to decrease excessive use or misuse of oxytocin exist, but it is 
unclear to what extent they have been adopted.  
 A persistent difficulty in the study of oxytocin is measurement. Many studies use 
“induction” or “augmentation” as variables, but both induction and augmentation are simply 
markers for an array of medications and procedures. The measures are heterogenous and the 
research findings are heterogenous due to a lack of specificity in measurement. While oxytocin 
would be best captured as a continuous variable, most studies use a binary variable (i.e., exposed 
to oxytocin – yes or no). In all of these studies, oxytocin exposure is measured as a binary 
variable33,35,72–76; further quantification of oxytocin exposure in the US among laboring women is 
not readily available. The use of a binary variable “loses” most of the information about a 
continuous variable. Recent studies have pioneered different measures, predominantly 
categorical, to better understand oxytocin use. There has been little methodological conversation, 
however, around the rationale behind these measures and which measure is best 
pharmacologically, physiologically and clinically. Several studies have used “total dose” to 
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measure oxytocin but ended up creating categories because the continuous variable was difficult 
to interpret clinically. One difficulty in these studies is a lack of consistent measurements (e.g., 
comparing percentiles50 of oxytocin dose to 5000 mU increases14). To add to the confusion, some 
studies have referred to “area under the curve” and others “total dose” to refer to the same 
measure. Researchers might consider using additional measures of oxytocin exposure that 
provide more information and greater clinical utility than a binary variable. Some examples 
include: total dose (mU); maximum infusion rate (mU/min); and total duration (min). Further 
research is needed to determine the best categorical measures of oxytocin exposure.  
 Initially, oxytocin exposure was going to be examined as a continuous variable (total 
dose, mU). Using this variable was difficult to interpret, however, so the decision was made to 
create two different categorical variables that would be easier to interpret clinically. The first 
variable created categories by 600 mU (the total dose of oxytocin in mU after an hour of 
receiving a 10 mU/min infusion) up to 9600 mU, followed by a category at 10800, 12000 and 
15000 mU. 10,800 mU was close to the 90th percentile for oxytocin exposure in the data set 
(10,914 mU) and equivalent to an additional hour of oxytocin exposure at 20 mU/min; 12,000 
mU was equivalent to an additional hour of exposure to a 20 mU/min oxytocin rate. 15000 mU 
was close to the 95th percentile (15,114 mU). In the dataset, the 25th percentile was 860 mU and 
the 50th percentile was 2,618 mU. The rationale in creating these categories was to have small 
increases that were clinically understandable. The second variable was infusion rate categories at 
≤ 10 mU/min, ≤ 20 mU/min, ≤ 40 mU/min and ≥ 40 mU/min. Again, these categories were 
created based on clinical relevance as most oxytocin policies have a maximum dose of 20 
mU/min or, less frequently, 40 mU/min. 
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Studies looking to examine induction or augmentation should parse the medications or 
practices being used so that the outcomes of the studies are easier to understand. Induction is 
“easy” to look at because it has an ICD-10 code, but the heterogeneity of induction practices and 
protocol makes it an unhelpful study variable. It is more difficult to examine augmentation as 
there is currently no associated ICD-10 code. Further, augmentation involves an array of 
practices and protocols which means that this, too, is not necessarily a helpful study variable. 
Future studies might delineate the specific procedure or medication being used to augment labor, 
the procedure or medication protocol and whether woman is being augmented before or after she 
is in active labor (>= 6 cm cervical dilation). 
  “Spontaneous labor” is frequently used as sample inclusion criteria in augmentation 
studies; but spontaneous labor does not necessarily mean active labor, which is perhaps the more 
relevant marker. Recent studies have demonstrated that labor should be called active when 
cervical dilation is greater than or equal to six centimeters. To improve clinical practice, better 
understand adverse effects related to oxytocin and enable comparison between studies, the new 
definition of active labor should be used consistently. 
While there is some inconsistency in the findings of these studies – due, in part, to the 
nature of the research questions and binary measurement of oxytocin – the overarching finding is 
that oxytocin exposure is an independent risk factor for postpartum hemorrhage. There is 
evidence that even two hours on a 20 mU/min infusion of oxytocin substantially increases the 
risk of severe postpartum hemorrhage, as does increasing the infusion rate above 20 mU/min. 
Further research is needed, however, to corroborate these findings, refine the understanding of 
oxytocin’s association with hemorrhage (e.g., are there clinically relevant points in oxytocin 
exposure where risk for hemorrhage increases exponentially? Are there points that are suggested 
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by the data, clinical practice or physiology?) and to translate these findings to inform clinical 
practice. One immediate suggestion, however, would be to include the potential increased risk 
for postpartum hemorrhage in providing informed consent to women around oxytocin use in 
labor.  
 To better understand the relationship between oxytocin exposure in labor and the risk of 
cesarean section, more detailed information about oxytocin is needed. Such variation exists in 
each woman’s exposure to oxytocin, that observing oxytocin exposure as a binary variable may, 
in fact, obscure more than it elucidates. 
While frequent use of oxytocin in the intrapartum is documented in a variety of high-
income countries, none of them have rates of maternal and neonatal morbidity and mortality as 
high as the United States. This suggests that while over- and inappropriate use of oxytocin may 
contribute in part to morbidity and poor-quality outcomes, it is not the entire story. More 
research is needed regarding decision-making and communication around oxytocin use in the 
intrapartum. The research should be woman-centered and include outcomes that are important to 
women.43 Well-delineated definitions and measures are essential and may also require further 
research to develop. 
 Practice changes are needed to shift obstetric culture and how we use oxytocin. Two 
related foci for change are using the minimal amount of oxytocin necessary and addressing 
misuse of oxytocin (e.g., augmentation without an indication). Checklists, partograms and 
turning oxytocin off in active labor hold promise as ways to address both misuse and 
overuse.41,57,97,111–115 Other potential interventions include one-on-one support, either with nurses 
or doulas.117,118  
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 Nurses have a critical role in practice change, as they are the care provider at the bedside, 
assessing the patient and, frequently, the one alerting the attending physician or midwife as to 
whether or not intervention is needed. Nurses advocate for their patients and are capable of 
tracking the total dose of oxytocin a woman has received or questioning a provider’s oxytocin 
order if it seems inappropriate or unsafe. Midwives are known for supporting physiologic birth 
and preventing unnecessary intervention, but the practice culture in which they work make affect 
their clinical decision-making.154 Nurses and midwives are both able to advocate for practice 
change, to question whether starting oxytocin is appropriate, to use partograms and a more 
conservative (i.e. 6 cm dilation) definition of active labor in determining whether intervention is 
appropriate. Finally, nurses and midwives are uniquely suited to educating women, providing 
them with information so that women can make a truly informed choice regarding intervention 
during their labors. 
 Oxytocin, the life-saving high-alert medication, is overused in US obstetric practice. If 
practice in other high-income countries is similar to US practice, it is mis-used as well, 
especially in the context of labor augmentation. Specific oxytocin total doses and infusion rates 
are associated with a greater risk of postpartum hemorrhage and primary cesarean section. The 
way oxytocin is currently used in US obstetrics is tied to many factors, patient, provider and 
hospital. It will take a culture-change in obstetrical care to shift how we use oxytocin, but such 
change is possible. Oxytocin use is tied to maternal morbidity and quality outcomes, but its use, 
while frequent in other high-resource countries, is not associated with the same degree of adverse 
maternal and neonatal outcomes as we see here in the US. Oxytocin is just a piece in a much 
larger jigsaw puzzle, but a critical piece and one amenable to intervention to improve outcomes. 
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Registered Nurse, January 2008 - Present 
• License in PA pending; License in MD inactive 
 
Advanced Life Support in Obstetrics Instructor, June 2013 - Present 
 
Neonatal Resuscitation Provider, 2010 - Present 
 
Basic Life Support Provider, 2006 - Present 
 
Precision Nutrition Level 1 Coach, In Progress 
 




AMERICAN COLLEGE OF NURSE-MIDWIVES, 2010 – Present 
 
AMERICAN NURSES ASSOCIATION, 2015 – Present 
 








Program Advisor, Master in Pastoral Care and Counseling Program, Antiochian House of Studies, 
UNIVERSITY OF BALAMAND, 2016 – Present 
• Provide health care expertise, research advice for students’ thesis work, curriculum 
feedback and participate in the students’ annual residency 
 
 
 
 
